Calpain-inhibiting peptide analogs of the kininogen heavy chain

Abstract

Synthetic peptide analogs of human kininogen are provided which are conformationally restricted by means of intramolecular bonding. The peptides mimic the biological activity of human kininogen by inhibiting the activity of the biologically significant protease, calpain. The peptides are designed by means of an equilibrium conformational model of the kininogen heavy chain.

Description

FIELD OF THE INVENTION

The invention relates to synthetic peptide analogs of the human plasma proteins, high and low molecular weight kininogen.

BACKGROUND OF THE INVENTION

Activation and aggregation of human platelets leads to the formation of blood clots (thrombi). It is well established that the binding of fibrinogen to specific receptors on platelets is essential for platelet aggregation. Unstimulated platelets do not bind fibrinogen and do not aggregate during circulation. When platelets are stimulated by certain physiological agonists, such as ADP, thrombin, etc., the fibrinogen receptors associated with the glycoprotein IIb/IIIa complex on the platelet become exposed, resulting in fibrinogen binding leading to platelet aggregation.

Aggregin (M.sub.r =100 kDa) is a putative ADP-receptor on the platelet surface. It has been shown to be completely cleaved during thrombin- and plasmin-induced platelet aggregation. The binding of thrombin and plasmin to their receptors on the platelet surface is a important requirement for these plasma proteases to elicit aggregin proteolysis and platelet aggregation.

Thrombin- and plasmin-induced platelet aggregation and cleavage of aggregin are indirectly mediated by intracellularly activated calpain expressed on the platelet surface. Thrombin- and plasmin-induced platelet aggregation are inhibited by cysteine protease inhibitors, including kininogens.

Kininogens exist in human plasma in two molecular forms, high molecular weight kininogen (HK) and low molecular weight kininogen (LK). HK is synthesized in the liver as a single chain and secreted into plasma at a concentration of 0.67 .mu.M. HK is cleaved by plasma kallikrein, resulting in the formation of (i) a 64 kDa heavy chain and a 56 kDa light chain linked by a single disulfide bond, and (ii) the nonapeptide bradykinin. The latter has multiple inflammatory effects including induction of pain, vasodilation and increased vascular permeability (Colman, J. Clin. Invest. 73, 1249-1253 (1984)). Studies of human mutants (e.g., Colman et al., J. Clin. Invest. 56, 1650-1662 (1975)) delineated the coagulant function of HK. LK, present in plasma at 2.4 .mu.M, releases bradykinin preferentially after exposure to tissue kallikrein, and does not exhibit coagulant activity. LK contains a short light chain of 4 kDa, and has a total molecular weight of 66 kDa, in contrast to the 56 kDa light chain and 120 kDa total weight of intact HK. Both HK and LK have an identical heavy chain which results from translation of alternately spliced mRNAs from a single gene.

The major function of the heavy chain of HK and LK is to inhibit proteases with cysteine at their active sites. Such cysteine proteases include the calcium-activated cysteine proteases, more commonly known as "cal-pains" (Schmaier et al., J. Clin. Invest. 77, 1565-1573 (1986)). The kininogen heavy chain contains three repeating units or "domains" having mutual sequence homology, designated D1, D2, and D3. The domains are derived evolutionarily from the more primitive stefins and cystatins by gene duplication. The crystal structure of chicken egg white cystatin has been solved by Bode et al., EMBO J., 7, 2593-2599 (1988).

Of the three kininogen heavy chain repeats, D2 and D3 contain the pentapeptide Gln-Val-Val-Ala-Gly ("QVVAG"). Although both D2 and D3 contain the QVVAG sequence and are inhibitors of cysteine proteinases, only D2 is effective in inhibiting calpain (Salvesen et al., Biochem. J. 234, 429-434 (1986); Muller-Esterl, Atemw.-Lungenkrkh. Jahrgang 14, 1. Suppl.-Heft S11S-S22 (1988). Teno et al., Int. J. Peptide Protein Res. 30, 93-98 (1987) report weak activity of the QVVAG pentapeptide in inhibiting the thiol protease papain.

Reocclusion of coronary arteries is a frequent complication following thrombolytic therapy. It has been postulated that reocclusion is due to plasmin-induced activation of platelets. High concentrations of plasmin, such as might occur in therapeutic thrombolysis, are known to cause platelet aggregation.

Coronary artery restenosis following angioplasty has been linked to platelet activation by protease agonists. Restenosis may be initiated by thrombin-stimulated release of growth factors from platelets.

What is needed is a method of inhibiting stimulation and aggregation of platelets by protease agonists, specifically a method of inhibiting stimulation of platelets by inhibiting the action of platelet calpain in facilitating thrombin- and plasmin-induced platelet aggregation.

SUMMARY OF THE INVENTION

A synthetic peptide is provided comprising an amino acid sequence corresponding to a portion of domain 2 of the human kininogen heavy chain. The peptide has a restricted conformation and the ability to inhibit the enzymatic activity of calpain.

In another embodiment, the invention is directed to a method of designing a peptide analog to the kininogen heavy chain domain. The distance between two parts of a molecular model of the kininogen heavy chain domain 2 is determined at conformational equilibrium. The primary structure of the domain is then modified to restrict that distance to the determined distance. A peptide comprising the modified primary structure is then synthesized.

In yet another embodiment of the invention, a method of producing a peptide having a restricted conformation is provided. Accordingly, a peptide having an amino acid sequence corresponding to a portion of the human kininogen heavy chain domain 2 is provided. The conformational equilibrium of a portion of that domain is determined. A covalent modification is introduced into the peptide to restrict a distance between two parts of the peptide to a distance between corresponding parts of the peptide in the equilibrium conformation determined.

The invention further provides pharmaceutical compositions comprising one or more of the peptides in combination with a pharmaceutically acceptable carrier. The activity of platelet calpain is inhibited by the peptides of the invention. Inhibition of platelet calpain results in the inhibition of thrombin- or plasmin-induced platelet aggregation of human platelets incubated with calpain-inhibiting agents.

By "human kininogen heavy chain" is meant the about 64 kDa polypeptide chain, common to both high molecular weight and low molecular weight human kininogen, which polypeptide is obtainable by kallikrein cleavage of high about 120 kDa major kallikrein cleavage fragment and isolation of the about 64 kDa single polypeptide chain therefrom.

By "domain 2" of human kininogen heavy chain is meant the region of the intact 64 kDa polypeptide chain comprising from about amino acid 124 to about amino acid 243 of the mature polypeptide. The mature polypeptide is generated by a post-translational modification which cleaves an 18-amino acid leader from the translated poly-peptide.

DESCRIPTION OF THE FIGURES

FIG. 1 is a plot of calpain inhibition by the following peptide, ##STR1## which peptide corresponds to human kininogen heavy chain amino acids 229 through 248, with an intramolecular disulfide bond connecting the cysteine residues.

DETAILED DESCRIPTION OF THE INVENTION

We have found that there is a specific site in the kininogen heavy chain, in addition to the QVVAG sequence, which is a binding or inhibitory site involved in calpain inhibition. The site lies within domain 2. The deduction of the structure of domain 2 was accomplished a homology-based molecular modeling technique reviewed by Jameson in Nature, 341, 465-466 (1989), based upon the published structure of cystatin (Bode et al., Embo J. 7, 2593-2599 (1988)). Cystatin, like kininogen, is a cysteine protease inhibitor. The modeled domain 2 structure is used as a design template for synthesizing peptides according to the present invention that are expected to adopt a conformational repertoire overlapping that of the native protein. The sequences identified herein from the kininogen heavy chain have not been previously identified as being inhibitory for cysteine proteases.

The calpain-inhibiting peptides of the invention are believed capable of selectively inhibiting platelet activation by thrombin and/or plasmin. Other peptides, such as the RGD-containing proteases, may inhibit platelet aggregation in response to cell agonists, but may also lead to prolonged bleeding times and hemorrhagic complications.

The primary structure of the kininogen heavy chain is known (Salveson et al., Biochem. J. 234, 429-434 (1986), incorporated herein by reference; Kellerman et al., J. Biochem. 154, 471-478 (1986)) incorporated herein by reference). While the significance of the QVVAG sequence as a weak inhibitor of papain is known (Tenno et al., Int. J. Peptide Protein Res. 30, 93-98 (1987)), the prior art attaches no functional significance to any other sequence as a potential inhibitor of calpain.

Traditional syntheses of the linear amino acid sequence of biologically interesting proteins may result in peptides that are either biologically inactive or, at best, marginally active. We have created a molecular model of the three-dimensional structure of heavy chain domain 2. The structure created in this manner is used as a template for designing conformationally-restricted synthetic analogs having calpain inhibiting activity. Using both distance and geometric constraints imparted through measurements of the subdomains within the calculated structure, constraints are artificially introduced, e.g., disulfide bonds, to limit the conformational freedom of a synthetic peptide that incorporates the relevant amino acids. One particular conformationally-restricted synthetic peptide analog having potent calpain inhibiting activity corresponds to kininogen heavy chain residues 211-230, according to the numbering of the amino acids of the mature polypeptide. The model disclosed herein may be utilized to prepare additional conformationally-restricted synthetic peptides having similar activity.

Appendix 1 hereto contains the set of Brookhaven coordinates and connect statement specifying our equilibrium conformation model of the major portion of kininogen heavy chain domain 2 comprising the 109 amino acids spanning positions 124 to 232, inclusive. The corresponding graphic molecular model satisfying these coordinates may be generated by inputting the coordinates and connect statement into any of the many commercially available molecular modeling programs which are capable of reading files in the Brookhaven format. Such programs include, for example, those of BioDesign, Inc., Pasadena, Calif.; Biosym Technologies, San Diego, Calif.; Tripos, St. Louis, Mo.; Polygen, Waltham, Ma.; and Chemical Design Ltd., Oxford, UK. The data may be entered as an ASCII file.

According to the Brookhaven format shown in the Appendix, each of the atoms of kininogen heavy chain residues 124-232 is assigned a number and respective X, Y and Z coordinates. The coordinate portion of the listing begins with the cysteine residue (CYS 1) at position 124 of the mature kininogen heavy chain. The atom types are identified as "N" for nitrogen, "HN" for hydrogen which is connected to a nitrogen atom, "C" for carbon, "CA" for .alpha. carbon, "CB" for .beta. carbon, "CG" for .gamma. carbon, and so forth. Identical atoms of branched side chains are indicated by numbers. Thus, the two .gamma. carbons of VAL 5 are designated "CG 1" and "CG 2" respectively.

The data file further comprises a connect statement which begins immediately after the coordinates for atom 1068. The connect statement identifies the covalent bonding pattern of each of the 1068 atoms. Thus, for example, the 10th entry of the connect statement (CONNECT 10) indicates that atom 10, which is the nitrogen atom of LEU 2 (corresponding to amino acid 125 of the mature kininogen heavy chain sequence), is bonded to atom 12 (the .alpha. carbon of the same residue), atom 6 (the carbonyl carbon of the neighboring cysteine residue), and atom 11 (hydrogen). The complete data file of 1,068 coordinates, together with the connect statement for these entries, specifies the equilibrium conformation of kininogen heavy chain domain 2.

The analogs of the invention generally have an amino acid sequence similar to the native domain 2 sequence. However, a covalent modification is introduced to restrict the analog to the conformation (or one close to it) displayed by the above model. Generally, this is accomplished by determining a distance between two non-contiguous parts of the amino acid chain according to the model. Then a chemical moiety is introduced to fix that determined distance in the analog. For example, a 5-6A distance can be fixed using a disulfide bond. Cysteine residues can be introduced at the appropriate positions in the model and then the new cysteine-containing model is tested for its ability to mimic the structure observed in the model.

The use of artificially introduced cysteine residues to create a disulfide bridge is one way to conformationally restrict the peptides. Disulfide bonds, however, are intrinsically unstable and it is difficult to obtain a homogeneous solution of intradisulfide-bonded species without concomitant mixed disulfides. The disulfide bridges can be replaced in biologically active peptides by stable covalent bonds. There are several strategies which can be utilized in the covalent closure of the peptides. Two of these strategies are described below.

The peptide can be internally crosslinked via the side chains of a lysine .epsilon.-amino group and the carboxylic acid function of a glutamic or aspartic acid side chain, thus creating an amide bond. The peptide is synthesized according to standard procedures on a low substitution (0.2 mM/gm or less) para-methylbenzhydrylamine resin. The first residue added to the resin is an N-.alpha.-tBOC,.epsilon.-fMOC lysine. The rest of the peptide synthesis is continued normally using tBOC chemistry until the final residue is added. The last residue to be added is a Z-protected glutamic acid, where the carboxylic acid moiety is protected with a tertbutyl group. Treatment of the peptide resin with piperidine/DMF removes the fMOC group from the .epsilon.-amino group of the initial lysine without affecting any other protection groups. Subsequent treatment with trifluoracetic acid removes the protection of the carboxylic acid group of the glutamic acid. Following neutralization, the peptide is covalently closed using a standard diimide-meditated coupling reaction. It should be emphasized that this is only one of the ways in which the synthetic peptide can be covalently closed.

Other fMOC/tBOC strategies include covalent closure of the peptide between two free amino groups utilizing toluene-2,4-diisocyanate (TDI), a heterobifunctional cross-linker. The methyl group of the aromatic ring of TDI prevents the isocyanate group in the 2 position from reacting at a pH 7.5 or below, whereas the isocyanate group in the para position is highly reactive. A shift in pH to greater than 9.0 will initiate a reaction with the isocyanate group in the 2 position, thus enabling highly specific and controlled conditions for covalent closure of the peptide. By utilizing a variety of different strategies for restricting the conformation of these peptides, distance geometries and orientation of the folded peptide can be controlled. Any such strategies employing chemical reactions known in the art may be used.

Using these techniques, synthetic peptide analogs can be made and tested for their ability to mimic the biological functions of the parent kininogen molecule, specificially, calpain inhibition.

One particularly useful peptide analog which was derived using the techniques described herein comprises amino acids 211-230 of the kininogen heavy chain. This peptide was restricted conformationally using cysteine-cysteine disulfide bonds, but other restricting means may be advantageously used. Peptide 211-230, crosslinked at cysteine residues 211 and 230, inhibits the activity of calpain, and, as a consequence, may be used to inhibit platelet activation by thrombin and/or plasmin. Methods of assaying calpain inhibition are known in the art. One such method is described hereinafter in Example 2. Another method is described in Example 19 of European Patent Application 393,457 (1990).

The present peptides are relatively short in length and therefore they are easily synthesized by chemical means. Such synthetic peptides have many advantages over the use of the entire kininogen heavy chain, or the entire D2 domain. Large portions of the heavy chain cannot conveniently be made by synthetic techniques and must be made by recombinant DNA techniques, which are expensive and time consuming. Additionally, proteins may present solubility and immunogenicity problems when introduced into a patient. Short synthetic peptides are much more soluble and less immunogenic than larger proteins.

As used herein, "peptide" refers to a linear series of no more than about 50 amino acid residues connected to one another by peptide bonds between the alpha-amino groups and carboxy groups of adjacent amino acid residues. Additional covalent bonds between portions of the peptide are also present to restrain the conformation of the molecule, such as amide and disulfide bonds. When used herein, "protein" refers to a linear series of greater than 50 amino acid residues connected one to the other as in a peptide. The term "synthetic peptide" means a chemically derived chain of amino acid residues linked together by peptide bonds that is free of naturally occurring proteins and fragments thereof.

The three-letter symbols used to represent the amino acid residues in the peptides of the present invention are those symbols commonly used in the art. The amino acid residues are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form may be substituted for any L-amino acid, as long as the desired functional property of calpain inhibition is retained by the peptide. The three-letter symbols used herein refer to the following amino acids: Ser is serine; Ile is isoleucine; Gln is glutamine; Phe is phenylalanine; His is histidine; Trp is tryptophan; Lys is lysine; Asn is asparagine; Leu is leucine; Gly is glycine; Thr is threonine; Asp is aspartic acid; Arg is arginine; and Ala is alanine.

Peptides of the present invention include any analog, fragment or chemical derivative of the peptides capable of inhibiting calpain. The term "analog" refers to any peptide having a substantially identical amino acid sequence to the peptides of the invention in which one or more amino acids have been substituted with other amino acids; the substituted amino acids allow or require the peptide to assume the equilibrium conformation of the domain of the parent protein. Often, cysteine, lysine and glutamic acid will be used for their side chains which can form covalent linkages to restrict the conformation of a peptide. In addition, conservative amino acid changes may be made which do not alter the biological function of the peptide. For instance, one polar amino acid, such as glycine, may be substituted for another polar amino acid; or one acidic amino acid, such as aspartic acid may be substituted for another acidic amino acid, such as glutamic acid; or a basic amino acid, such as lysine, arginine or histidine may be substituted for another basic amino acid; or a non-polar amino acid, such as alanine, leucine or isoleucine may be substituted for another non-polar amino acid.

The term "analog" shall also include any peptide which has one or more amino acids deleted from or added to an amino acid sequence of kininogen heavy chain domain 2, but which still retains a substantial amino acid sequence homology to kininogen, as well as kininogen's calpain inhibiting activity. A substantial sequence homology is any homology greater than 50% but preferably greater than 90%. The term "fragment" shall refer to any shorter version of the peptides identified herein having at least five amino acid residues, wherein the fragment is capable of inhibiting calpain.

The peptides of the present invention may be prepared by any of the following known techniques. Conveniently, the peptides may be prepared using the solid-phase synthetic technique initially described by Merrifield, in J. Am. Chem. Soc. 15, 2149-2154 (1963). Other peptide synthesis techniques may be found, for example, in M. Bodanszky et al., Peptide Synthesis, John Wiley & Sons, 2d Ed. (1976) as well as in other reference works known to those skilled in the art. A summary of peptide synthesis techniques may be found in J. Stuart and J. D. Young, Solid Phase Peptide Synthelia, Pierce Chemical Company, Rockford, Ill. (1984). The synthesis of peptides by solution methods may also be used, as described in The Proteins, vol- II, 3d Ed., Neurath, H. et al., Eds., p. 105-237, Academic Press, New York, NY. (1976). Appropriate protective groups for use in such syntheses will be found in the above texts as well as in J. F. W. McOmie, Protective Groups in Organic Chemistry, Plenum Press, New York, NY. (1973). Of course, the present peptides may also be prepared by recombinant DNA techniques, although such methods are not preferred because of the need for purification and subsequent chemical modifications to conformationally restrain the peptides.

In general, these synthetic methods involve the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid residue is protected by a suitable, selectively-removable protecting group. A different, selectively-removable protecting group is utilized for amino acids containing a reactive side group, such as lysine.

Using a solid phase synthesis as an example, the protected or derivatized amino acid is attached to an inert solid support through its unprotected carboxyl or amino group. The protecting group of the amino or carboxyl group is then selectively removed and the next amino acid in the sequence having the complementary (amino or carboxyl) group suitably protected is admixed and reacted under conditions suitable for forming the amide linkage with the residue already attached to the solid support. The protecting group of the amino or carboxyl group is then removed from this newly added amino acid residue, and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining terminal and side group protecting groups (and solid support) are removed sequentially or concurrently, to provide the final peptide. The peptides of the invention are devoid of benzylated or methylbenzylated amino acids. Such protecting group moieties may be used in the course of synthesis, but they are removed before the peptides are used. Additional reactions may be necessary, as described elsewhere to form intramolecular linkages to restrain conformation.

The peptides of the present invention generally contain at least five amino acid residues and up to fifty amino acid residues, preferably between 6 and 20 amino acid residues. These peptides may be linked to an additional sequence of amino acids either or both at the N-terminus and at the C-terminus, wherein the additional sequences are from 1-100 amino acids in length. Such additional amino acid sequences, or linker sequences, can be conveniently affixed to a detectable label or solid matrix, or carrier. Typical amino acid residues used for linking are tyrosine, cysteine, lysine, glutamic acid and aspartic acid, or the like.

Any peptide of the present invention may be used in the form of a pharmaceutically acceptable salt. Suitable acids which are capable of forming salts with the peptides of the present invention include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid or the like.

Suitable bases capable of forming salts with the peptides of the present invention include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such a mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanolamines (e.g., ethanolamine, diethanolamine and the like).

For use in a method of treatment, such as treatment for inhibiting thrombin- or plasmin-induced platelet aggregation, the synthetic peptides of the present invention may be present in a pharmaceutical composition in admixture with a pharmaceutically-acceptable carrier. The pharmaceutical composition may be compounded according to conventional pharmaceutical formulation techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., sublingual, rectal, nasal, oral or parenteral. Compositions for oral dosage form may include any of the usual pharmaceutical media, such as, for example, water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (e.g., suspensions, elixirs and solutions) or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (e.g., powders, capsules and tablets). Controlled release forms may also be used. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.

For compositions to be administered parenterally, the carrier will usually comprise sterile water, although other ingredients to aid solubility or for preservation purposes may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The parenteral routes of administration may be intravenous injection, intramuscular injection or subcutaneous injection.

For intravenous administration, the peptides may be dissolved in an appropriate intravenous delivery vehicle containing physiologically compatible substances such as sodium chloride, glycine and the like, having a buffered pH compatible with physiologic conditions. Such intravenous delivery vehicles are known to those skilled in the art.

The peptides of the invention may be administered to subjects in any situation where inhibition of calpain activity is desired. Calpain inhibitors may be administered during or after angioplasty or thrombolytic therapy to prevent restenosis or reocclusion. It is believed that restenosis following angioplasty may be initiated by thrombin-stimulated release of growth factors from platelets. Reocclusion, a frequent occurrence after thrombolytic therapy, has been postulated to be caused by plasmin-induced activation of platelets, which is mediated by platelet calpain.

The peptides may be administered by any convenient means which will result in the delivery to the bloodstream of a calpain-inhibiting effective amount. Intravenous administration is presently contemplated as the preferred administration route. The amount administered will depend on the activity of the particular compound administered, which may readily be determined by those of ordinary skill in the art. Generally, the peptides may be administered in an amount sufficient to provide a plasma concentration in the range of from about 10 to about 500 .mu.M, more preferably in the range of from about 50 to about 250 .mu.M. Plasma concentrations higher or lower than these may be utilized, depending upon the activity of the particular compound being administered, and the nature of the treatment.

In addition to inhibition of plasmin- and thrombin-induced platelet aggregation, inhibitors of calpain have other beneficial therapeutic utilities. Abnormal activation of calpain has been linked to diverse disease conditions, such as muscular dystrophy and cataracts. Furthermore, inhibitors of calpain have been shown to be able to limit brain damage caused by the interruption of the supply of blood and oxygen to the brain. Tests with calpain inhibitors in model systems have indicated that inhibition of calpain alone is sufficient to protect brain cells from ischemic damage after ischemic attack. It is contemplated that the peptides of the present invention are useful in any therapeutic circumstance where reduction of calpain activity is desired.

The following non-limiting examples serve to illustrate the practice of the invention.

EXAMPLE 1

This example demonstrates the selection and synthesis of a calpain-inhibiting kininogen analog.

The modeled structure of Appendix 1 was used as a design template in the construction of an analog corresponding to kininogen heavy chain residues 211-230. In order to conformationally restrict the folding equilibria of the resulting synthetic peptide, the cysteine residues at positions 211 and 230 were allowed to form an intrachain disulfide bond in computer-assisted modeling. The predicted folding pattern of the putative structure was tested for its ability to mimic the structure observed in our model of domain 2. Finding satisfactory agreement, the peptide was synthesized according to conventional solid phase procedures. The peptide incorporated the native residues 211-230, with a disulfide residue bond connecting the cysteine residues at positions 211 and 230. The peptide assayed pure upon high performance liquid chromatography. The intrachain disulfide bond was spontaneously formed by diluting the synthesized peptide to a concentration of 100 .mu.g/ml in a solution adjusted to pH 8.5 with NH.sub.4 OH, followed by stirring open to the atmosphere to ensure oxidation. The resulting disulfide-bonded peptide was then lyophilized.

EXAMPLE 2

This example demonstrates the biological activities of the peptide analogs.

The calpain-inhibiting activity of the disulfide-bonded Example 1 peptide was demonstrated according to a modification of the procedure of Schmaier et al., J. Clin. Invest. 77, 1565 (1986). A calpain preparation (5.about.10 .mu.l) was placed on a floating filter membrane (Marusyk et al., Anal. Biochem. 105, 403 (1980)) (Millipore type VMWP) over a buffer containing 50 mM Tris/HCl, pH 7.5 and 2.5 mM EDTA for 45-60 minutes, then carefully removed and used for the following inhibition study. Aliquots (25 .mu.l) of the enzyme (calpain) and buffer or synthetic peptide were added to a cuvette at 25.degree. C. containing 1mM succinyl-Leu-Tyr-amino-4-methylcumarin as the substrate in a buffer consisting of 60 mM Tris/HCl, pH 7.5, 2.5% DMSO and 5mM CaCl.sub.2. The rate of substrate hydrolysis was continuously recorded on a Perkin-Elmer LS-5 fluorescence spectrophotometer connected to a R100 chart recorder. The absorbance maximum of substrate occurred at 380 nm and emission maximum was observed at 450 nm. The data, forming a dose-dependent curve, was plotted in FIG. 1. The IC.sub.50 calculated from FIG. 1 corresponds to that concentration of inhibitory peptide that produced 50% inhibition of calpain activity. The subject peptide inhibited calpain activity with an IC.sub.50 of 26 .mu.M.

All references with respect to synthetic, preparative and analytic procedures are incorporated herein by reference.

The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

APPENDIX 1______________________________________Kininogen Heavy Chain Domain 2______________________________________ATOM 1 N CYS 1 148.352 83.819 84.352ATOM 2 HN CYS 1 149.065 83.809 84.469ATOM 3 HN CYS 1 147.668 82.917 84.631ATOM 4 HN CYS 1 147.824 83.997 83.373ATOM 5 CA CYS 1 147.470 84.875 85.190ATOM 6 C CYS 1 147.825 86.268 84.842ATOM 7 O CYS 1 146.840 86.969 84.504ATOM 8 CB CYS 1 147.644 84.558 86.684ATOM 9 SG CYS 1 146.110 84.227 87.512ATOM 10 N LEU 2 149.077 86.741 84.892ATOM 11 HN LEU 2 149.734 86.089 85.056ATOM 12 CA LEU 2 149.566 88.045 84.751ATOM 13 C LEU 2 148.668 89.216 84.556ATOM 14 O LEU 2 148.323 89.566 83.403ATOM 15 CB LEU 2 150.948 88.103 84.078ATOM 16 CG LEU 2 151.989 88.607 85.388ATOM 17 CD1 LEU 2 152.870 87.455 85.583ATOM 18 CD2 LEU 2 152.865 89.687 84.451ATOM 19 N GLY 3 148.176 89.956 85.546ATOM 20 HN GLY 3 147.620 93.678 85.315ATOM 21 CA GLY 3 148.425 89.744 86.899ATOM 22 C GLY 3 147.373 93.110 87.855ATOM 23 O GLY 3 147.594 91.136 88.542ATOM 24 N CYS 4 146.233 89.466 88.067ATOM 25 HN CYS 4 145.730 89.717 88.819ATOM 26 CA CYS 4 145.657 88.447 87.302ATOM 27 C CYS 4 144.407 88.893 86.629ATOM 28 O CYS 4 144.267 88.580 85.428ATOM 29 CB CYS 4 145.512 87.173 88.159ATOM 30 SG CYS 4 144.869 85.790 87.252ATOM 31 N VAL 5 143.398 89.595 87.138ATOM 32 CA VAL 5 143.310 93.159 88.410ATOM 33 C VAL 5 142.944 89.243 89.505ATOM 34 O VAL 5 143.802 89.121 90.419ATOM 35 CB VAL 5 142.824 91.626 88.411ATOM 36 CG1 VAL 5 141.331 91.877 88.673ATOM 37 CG2 VAL 5 143.681 92.475 89.357ATOM 38 N HIS 6 141.780 88.605 89.495ATOM 39 HN HIS 6 141.248 88.691 88.725ATOM 40 CA HIS 6 141.277 87.824 90.533ATOM 41 C HIS 6 141.564 86.374 90.452ATOM 42 O HIS 6 142.278 86.055 91.436ATOM 43 CB HIS 6 139.820 88.188 90.854ATOM 44 CG HIS 6 139.748 89.140 91.966ATOM 45 ND1 HIS 6 139.722 90.444 91.890ATOM 46 HND1 HIS 6 139.754 90.942 91.094ATOM 47 CD2 HIS 6 139.693 88.811 93.310ATOM 48 CE1 HIS 6 139.643 90.946 93.098ATOM 49 NB2 HIS 6 139.620 89.950 93.959ATOM 50 N PRO 7 141.170 85.479 89.513ATOM 51 CA PRO 7 141.451 84.106 89.445ATOM 52 C PRO 7 142.406 83.428 90.357ATOM 53 O PRO 7 143.645 83.452 90.136ATOM 54 CB PRO 7 141.573 83.761 87.956ATOM 55 CG PRO 7 140.747 84.851 87.278ATOM 56 CD PRO 7 140.376 85.806 88.414ATOM 57 N ILE 8 142.067 82.756 91.454ATOM 58 HN ILE 8 142.795 82.371 91.906ATOM 59 CA ILE 8 140.820 82.514 92.071ATOM 60 C ILE 8 139.579 82.532 91.276ATOM 61 O ILE 8 138.880 83.575 91.257ATOM 62 CB ILE 8 140.613 82.952 93.545ATOM 63 CG1 ILE 8 141.247 84.268 94.032ATOM 64 CG2 ILE 8 140.957 81.795 94.485ATOM 65 CD1 ILE 8 140.175 85.340 94.261ATOM 66 N SER 9 139.281 81.419 90.612ATOM 67 HN SER 9 139.846 80.683 90.762ATOM 68 CA SER 9 138.231 81.215 89.710ATOM 69 C SER 9 137.725 79.819 89.684ATOM 70 O SER 9 138.498 78.850 89.469ATOM 71 CB SER 9 138.671 81.688 88.315ATOM 72 OG SER 9 137.761 82.640 87.792ATOM 73 HOG SER 9 137.609 83.392 88.401ATOM 74 N THR 10 136.472 79.421 89.873ATOM 75 HN THR 10 136.323 78.500 89.754ATOM 76 CA THR 10 135.338 80.157 90.230ATOM 77 C THR 10 134.536 80.843 89.190ATOM 78 O THR 10 133.354 80.431 89.070ATOM 79 CB THR 10 135.308 80.619 91.706ATOM 80 OG1 THR 10 134.020 80.455 92.283ATOM 81 HOG1 THR 10 133.484 81.251 92.087ATOM 82 CG2 THR 10 135.838 82.029 91.989ATOM 83 N GLN 11 135.020 81.822 88.423ATOM 84 HN GLN 11 135.944 81.984 88.422ATOM 85 CA GLN 11 134.342 82.697 87.567ATOM 86 C GLN 11 133.573 83.774 88.235ATOM 87 O GLN 11 132.376 83.584 88.552ATOM 88 CB GLN 11 133.780 82.094 86.264ATOM 89 CG GLN 11 134.033 82.999 85.042ATOM 90 CD GLN 11 135.408 82.982 84.526ATOM 91 OE1 GLN 11 136.289 83.706 85.047ATOM 92 NE2 GLN I1 135.735 82.218 83.511ATOM 93 HNE2 GLN 11 136.618 82.217 83.192ATOM 94 HNE2 GLN 11 135.087 81.671 83.106ATOM 95 N SER 12 134.078 84.967 88.528ATOM 96 HN SER 12 133.556 85.557 89.040ATOM 97 CA SER 12 135.333 85.440 88.146ATOM 98 C SER 12 136.184 85.763 89.313ATOM 99 O SER 12 137.126 84.940 89.430ATOM 100 CB SER 12 135.237 86.488 87.028ATOM 101 OG SER 12 136.336 86.349 86.140ATOM 102 HOG SER 12 136.325 85.445 85.761ATOM 103 N PRO 13 136.042 86.780 90.192ATOM 104 CA PRO 13 136.409 86.699 91.547ATOM 105 C PRO 13 135.691 85.729 92.410ATOM 106 O PRO 13 136.371 85.208 93.333ATOM 107 CB PRO 13 136.365 88.128 92.102ATOM 108 CG PRO 13 136.111 89.016 90.889ATOM 109 CD PRO 13 135.526 88.035 89.876ATOM 110 N ASP 14 134.403 85.425 92.225ATOM 111 HN ASP 14 133.941 85.896 91.558ATOM 112 CA ASP 14 133.624 84.476 92.899ATOM 113 C ASP 14 132.476 84.002 92.090ATOM 114 O ASP 14 132.496 82.802 91.733ATOM 115 CB ASP 14 133.243 84.950 94.313ATOM 116 CG ASP 14 132.847 83.961 95.318ATOM 117 OD1 ASP 14 133.195 82.761 95.333ATOM 118 OD2 ASP 14 132.102 84.364 96.228ATOM 119 N LEU 15 131.401 84.669 91.664ATOM 120 HN LEU 15 130.765 84.155 91.202ATOM 121 CA LEU 15 131.087 86.026 91.806ATOM 122 C LEU 15 132.080 87.008 91.291ATOM 123 O LEU 15 132.652 86.804 90.192ATOM 124 CB LEU 15 129.699 86.206 91.166ATOM 125 CG LEU 15 128.864 87.292 91.851ATOM 126 CD1 LEU 15 128.412 88.319 90.810ATOM 127 CD2 LEU 15 127.641 86.665 92.523ATOM 128 N GLU 16 132.481 88.141 91.872ATOM 129 HN GLU 16 133.174 88.581 91.413ATOM 130 CA GLU 16 132.065 88.807 93.035ATOM 131 C GLU 16 133.005 89.892 93.456ATOM 132 O GLU 16 134.120 89.535 93.944ATOM 133 CB GLU 16 131.554 87.987 94.244ATOM 134 CG GLU 16 130.229 88.426 94.900ATOM 135 CD GLU 16 129.810 89.815 94.693ATOM 136 OE1 GLU 16 128.932 90.088 93.848ATOM 137 OE2 GLU 16 130.322 90.750 95.349ATOM 138 N PRO 17 132.749 91.218 93.352ATOM 139 CA PRO 17 133.473 92.249 93.987ATOM 140 C PRO 17 133.728 92.219 95.449ATOM 141 O PRO 17 134.899 92.555 95.783ATOM 142 CB PRO 17 132.865 93.586 93.541ATOM 143 CG PRO 17 132.018 93.218 92.329ATOM 144 CD PRO 17 131.712 91.742 92.575ATOM 145 N ILE 18 132.796 91.870 96.345ATOM 146 HN ILE 18 132.002 91.504 96.000ATOM 147 CA ILE 18 132.843 91.993 97.754ATOM 148 C ILE 18 134.088 91.636 98.463ATOM 149 O ILE 18 134.605 90.492 98.334ATOM 150 CB ILE 18 131.564 91.674 98.576ATOM 151 CG1 ILE 18 130.936 90.281 98.356ATOM 152 CG2 ILE 18 130.548 92.826 98.457ATOM 153 CD1 ILE 18 130.260 89.642 99.578ATOM 154 N LEU 19 134.607 92.599 99.223ATOM 155 HN LEU 19 134.090 93.383 99.276ATOM 156 CA LEU 19 135.802 92.638 99.955ATOM 157 C LEU 19 135.769 92.273 101.386ATOM 158 O LEU 19 135.996 93.185 102.210ATOM 159 CB LEU 19 137.134 92.325 99.237ATOM 160 CG LEU 19 137.621 93.422 98.272ATOM 161 CD1 LEU 19 138.172 94.664 98.988ATOM 162 CD2 LEU 19 138.748 92.854 97.409ATOM 163 N ARG 20 135.540 91.110 101.974ATOM 164 HN ARG 20 135.629 91.095 102.909ATOM 165 CA ARG 20 135.181 89.915 101.369ATOM 166 C ARG 20 134.019 89.294 102.048ATOM 167 O ARG 20 132.939 89.331 101.422ATOM 168 CB ARG 20 136.413 89.009 101.198ATOM 169 CG ARG 20 136.187 87.996 100.074ATOM 170 CD ARG 20 137.321 88.062 99.051ATOM 171 NE ARG 20 137.046 88.933 97.995ATOM 172 HNE ARG 20 136.258 89.440 98.076ATOM 173 CZ ARG 20 137.774 89.123 96.896ATOM 174 NH1 ARG 20 138.935 88.588 96.566ATOM 175 HNH1 ARG 20 139.305 88.868 95.751ATOM 176 HNH1 ARG 20 139.367 87.962 97.118ATOM 177 NH2 ARG 20 137.328 89.947 95.979ATOM 178 HNH2 ARG 20 137.874 90.059 95.224ATOM 179 HNH2 ARG 20 136.513 90.404 96.070ATOM 180 N HIS 21 133.971 88.700 103.238ATOM 181 HN HIS 21 133.147 88.348 103.520ATOM 182 CA HIS 21 135.027 88.530 104.128ATOM 183 C HIS 21 135.175 87.127 104.573ATOM 184 O HIS 21 136.253 86.561 104.277ATOM 185 CB HIS 21 135.014 89.577 105.257ATOM 186 CG HIS 21 136.366 90.019 105.617ATOM 187 ND1 HIS 21 137.078 93.937 105.017ATOM 188 HND1 HIS 21 136.835 91.441 104.272ATOM 189 CD2 HIS 21 137.129 89.533 106.668ATOM 190 CE1 HIS 21 138.238 91.045 105.620ATOM 191 NE2 HIS 21 138.268 90.188 106.619ATOM 192 N GLY 22 134.339 86.344 105.242ATOM 193 HN GLY 22 134.686 85.483 105.374ATOM 194 CA GLY 22 133.074 86.640 105.746ATOM 195 C GLY 22 131.974 86.456 104.780ATOM 196 O GLY 22 131.560 87.470 104.171ATOM 197 N ILE 23 131.354 85.323 104.482ATOM 198 HN ILE 23 130.708 85.349 103.799ATOM 199 CA ILE 23 131.517 84.056 105.054ATOM 200 C ILE 23 131.846 82.938 104.141ATOM 201 O ILE 23 132.857 82.283 104.474ATOM 202 CB ILE 23 130.529 83.610 106.167ATOM 203 CG1 ILE 23 129.179 84.337 106.337ATOM 204 CG2 ILE 23 131.257 83.609 107.518ATOM 205 CD1 ILE 23 128.028 83.575 105.673ATOM 206 N GLN 24 131.273 82.471 103.029ATOM 207 HN GLN 24 131.598 81.629 102.774ATOM 208 CA GLN 24 130.283 82.981 102.173ATOM 209 C GLN 24 130.202 84.442 101.902ATOM 210 O GLN 24 129.337 85.171 102.456ATOM 211 CB GLN 24 128.931 82.288 102.439ATOM 212 CG GLN 24 128.644 81.061 101.555ATOM 213 CD GLN 24 129.044 79.742 102.374ATOM 214 OE1 GLN 24 129.201 79.471 103.292ATOM 215 NE2 GLN 24 129.246 78.782 101.205ATOM 216 HNE2 GLN 24 129.449 77.911 101.494ATOM 217 HNE2 GLN 24 129.188 78.977 100.287ATOM 218 N TYR 25 130.968 85.166 101.103ATOM 219 HN TYR 25 130.725 86.074 131.069ATOM 220 CA TYR 25 132.067 84.848 100.305ATOM 221 C TYR 25 133.197 84.120 100.938ATOM 222 O TYR 25 133.688 84.502 102.036ATOM 223 CB TYR 25 132.499 86.262 99.881ATOM 224 CG TYR 25 133.308 86.460 98.681ATOM 225 CD1 TYR 25 132.904 87.542 97.872ATOM 226 CD2 TYR 25 134.426 85.656 98.338ATOM 227 CE1 TYR 25 133.651 87.860 96.725ATOM 228 CE2 TYR 25 135.172 85.966 97.179ATOM 229 CZ TYR 25 134.770 87.069 96.396ATOM 230 OH TYR 25 135.449 87.413 95.289ATOM 231 HOH TYR 25 135.079 88.161 94.777ATOM 232 N PHE 26 133.785 83.042 100.434ATOM 233 HN PHE 26 134.434 82.639 100.982ATOM 234 CA PHE 26 133.572 82.428 99.190ATOM 235 C PHE 26 132.311 81.676 98.974ATOM 236 O PHE 26 131.740 81.098 99.940ATOM 237 CB PHE 26 134.797 81.519 98.983ATOM 238 CG PHE 26 135.646 81.851 97.835ATOM 239 CD1 PHE 26 136.516 82.972 97.866ATOM 240 CD2 PHE 26 135.597 81.021 96.688ATOM 241 CE1 PHE 26 137.349 83.258 96.755ATOM 242 CE2 PHE 26 136.423 81.300 95.572ATOM 243 CZ PHE 26 137.294 82.417 95.616ATOM 244 N ASN 27 131.809 81.634 97.738ATOM 245 HN ASN 27 132.286 82.081 97.065ATOM 246 CA ASN 27 130.640 81.016 97.268ATOM 247 C ASN 27 130.241 79.680 97.794ATOM 248 O ASN 27 129.138 79.517 98.399ATOM 249 CB ASN 27 129.555 82.110 97.138ATOM 250 CG ASN 27 129.087 82.331 95.767ATOM 251 OD1 ASN 27 128.029 81.791 95.374ATOM 252 ND2 ASN 27 129.764 83.100 94.950ATOM 253 HND1 ASN 27 129.471 83.245 94.069ATOM 254 HND2 ASN 27 130.549 83.501 95.273ATOM 255 N ASN 28 134.080 78.657 97.601ATOM 256 HN ASN 28 131.863 78.836 97.114ATOM 257 CA ASN 28 130.907 77.345 98.057ATOM 258 C ASN 28 132.084 76.737 98.723ATOM 259 O ASN 28 131.972 76.597 99.960ATOM 260 CB ASN 28 130.176 76.464 97.024ATOM 261 CG ASN 28 129.136 75.630 97.633ATOM 262 OD1 ASN 28 129.430 74.489 98.050ATOM 263 ND2 ASN 28 127.900 76.061 97.741ATOM 264 HND2 ASN 28 127.241 75.509 98.122ATOM 265 HND2 ASN 28 127.678 76.924 97.441ATOM 266 N ASN 29 133.242 76.323 98.206ATOM 267 HN ASN 29 133.864 75.949 98.803ATOM 268 CA ASN 29 133.575 76.417 96.854ATOM 269 C ASN 29 133.758 75.144 96.122ATOM 270 O ASN 29 132.816 74.832 95.360ATOM 271 CB ASN 29 134.605 77.530 96.583ATOM 272 CG ASN 29 134.572 78.097 95.229ATOM 273 OD1 ASN 29 135.458 77.768 94.410ATOM 274 ND2 ASN 29 133.643 78.947 94.857ATOM 275 HD2 ASN 29 133.707 79.366 94.019ATOM 276 HND2 ASN 29 132.923 79.140 95.429ATOM 277 N THP 30 134.763 74.275 96.142ATOM 278 HN THR 30 134.708 73.570 95.523ATOM 279 CA THR 30 135.889 74.269 96.971ATOM 280 C THR 30 137.118 74.919 96.455ATOM 281 O THR 30 137.566 74.647 95.303ATOM 282 CB THR 30 136.035 72.867 97.610ATOM 283 OG1 THR 30 136.578 72.970 98.914ATOM 284 HOG1 TRR 30 136.126 73.688 99.403ATOM 285 CG2 THR 30 136.784 71.770 96.831ATOM 286 N GLN 31 137.702 75.794 97.270ATOM 287 HN GLN 31 137.343 75.863 98.136ATOM 288 CA GLN 31 138.786 76.620 96.963ATOM 289 C GLN 31 139.818 76.728 98.029ATOM 290 O GLN 31 140.905 76.142 97.818ATOM 291 CB GLN 31 138.223 77.963 96.452ATOM 292 CG GLN 31 138.989 78.654 95.308ATOM 293 CD GLN 31 139.169 77.988 94.009ATOM 294 OE1 GLN 31 140.337 77.832 93.577ATOM 295 NE2 GLN 31 138.161 77.564 93.279ATOM 296 HNE2 GLN 31 138.314 77.186 92.432ATOM 297 HNE2 GLN 31 137.286 77.639 93.613ATOM 298 N HIS 32 139.169 77.371 99.194ATOM 299 HN HIS 32 140.540 77.577 99.657ATOM 300 CA HIS 32 138.585 77.789 99.817ATOM 301 C HIS 32 138.424 79.236 100.011ATOM 302 O HIS 32 137.392 79.688 99.458ATOM 303 CB HIS 32 138.288 76.977 101.091ATOM 304 CG HIS 32 137.112 76.103 100.983ATOM 305 ND1 HIS 32 136.933 75.027 101.694ATOM 306 HND1 HIS 32 137.557 74.692 102.312ATOM 307 CD2 HIS 32 136.000 76.219 100.154ATOM 308 CE1 HIS 32 135.769 74.495 101.404ATOM 309 NE2 HIS 32 135.223 75.199 100.429ATOM 310 N SER 33 139.280 80.003 100.706ATOM 311 HN SER 33 140.128 79.622 100.837ATOM 312 CA SER 33 139.035 81.286 101.245ATOM 313 C SER 33 138.012 81.362 102.321ATOM 314 O SER 33 137.015 80.585 102.326ATOM 315 CB SER 33 138.852 82.380 100.174ATOM 316 OG SER 33 139.751 83.468 100.337ATOM 317 HOG SER 33 139.680 83.853 101.235ATOM 318 N SER 34 138.150 82.270 103.292ATOM 319 HN SER 34 138.767 82.961 103.141ATOM 320 CA SER 34 137.495 82.374 104.533ATOM 321 C SER 34 137.616 81.279 105.523ATOM 322 O SER 34 137.874 81.613 106.708ATOM 323 CB SER 34 136.068 82.921 104.379ATOM 324 OG SER 34 135.800 83.871 105.397ATOM 325 HOG SER 34 135.972 84.769 105.043ATOM 326 N TYR 35 137.451 80.018 105.138ATOM 327 HN TYR 35 137.297 79.962 104.213ATOM 328 CA TYR 35 137.473 78.841 105.902ATOM 329 C TYR 35 138.829 78.296 106.128ATOM 330 O TYR 35 139.580 77.993 105.155ATOM 331 CB TYR 35 136.501 77.724 105.433ATOM 332 CG TYR 35 135.286 78.119 104.707ATOM 333 CD1 TYR 35 134.083 78.401 105.405ATOM 334 CD2 TYR 35 135.357 78.215 103.296ATOM 335 CE1 TYR 35 132.959 78.867 104.683ATOM 336 CE2 TYR 35 134.250 78.712 102.576ATOM 337 CZ TYR 35 133.073 79.049 103.283ATOM 338 OH TYR 35 132.045 79.552 102.571ATOM 339 HOH TYR 35 131.144 79.645 102.943ATOM 340 N PHE 36 139.206 78.142 107.393ATOM 341 HN PHE 36 138.622 78.474 108.052ATOM 342 CA PHE 36 140.379 77.528 107.844ATOM 343 C PHE 36 140.230 76.070 108.056ATOM 344 O PHE 36 139.340 75.613 108.830ATOM 345 CB PHE 36 140.974 78.329 109.022ATOM 346 CG PHE 36 142.151 77.734 109.668ATOM 347 CD1 PHE 36 143.389 77.621 108.980ATOM 348 CD2 PHE 36 142.028 77.267 111.002ATOM 349 CE1 PHE 36 144.499 77.014 109.617ATOM 350 CE2 PHE 36 143.138 76.666 111.646ATOM 351 CZ PHE 36 144.363 76.542 110.945ATOM 352 N MET 37 141.086 75.295 107.389ATOM 353 HN MET 37 141.749 75.742 106.894ATOM 354 CA MET 37 141.141 73.892 107.324ATOM 355 C MET 37 140.142 73.243 106.450ATOM 356 O MET 37 138.905 73.386 106.652ATOM 357 CB MET 37 141.436 73.144 108.645ATOM 358 CG MET 37 142.856 73.370 109.192ATOM 359 SD MET 37 144.093 72.637 108.154ATOM 360 CE MET 37 145.619 73.083 108.932ATOM 361 N LEU 38 140.642 72.515 105.453ATOM 362 HN LEU 38 141.562 72.329 105.516ATOM 363 CA LEU 38 140.004 71.995 104.315ATOM 364 C LEU 38 139.865 72.996 103.240ATOM 365 O LEU 38 139.057 73.960 103.358ATOM 366 CB LEU 38 138.798 71.052 104.532ATOM 367 CG LEU 38 138.546 70.138 103.324ATOM 368 CD1 LEU 38 138.327 68.701 103.803ATOM 369 CD2 LEU 38 137.309 70.600 102.544ATOM 370 N ASN 39 140.650 72.793 102.183ATOM 371 HN ASN 39 141.075 71.955 102.139ATOM 372 CA ASN 39 140.928 73.684 101.135ATOM 373 C ASN 39 141.672 74.931 101.479ATOM 374 O ASN 39 141.846 75.256 102.694ATOM 375 CB ASN 39 139.759 73.766 100.130ATOM 376 CG ASN 39 139.887 72.825 99.012ATOM 377 OD1 ASN 39 139.611 71.609 99.152ATOM 378 ND2 ASN 39 140.293 73.276 97.853ATOM 379 HND2 ASN 39 140.380 72.699 97.115ATOM 380 HND2 ASN 39 140.495 74.190 97.778ATOM 381 N GLU 40 142.170 75.707 100.510ATOM 382 HN GLU 40 141.820 75.628 99.642ATOM 383 CA GLU 40 143.189 76.661 100.667ATOM 384 C GLU 40 142.876 78.012 100.139ATOM 385 O GLU 40 141.946 78.639 100.732ATOM 386 CB GLU 40 144.626 76.089 100.521ATOM 387 CG GLU 40 144.999 75.298 99.246ATOM 388 CD GLU 40 145.029 76.034 97.977ATOM 389 OE1 GLU 40 145.691 77.083 97.810ATOM 390 OE2 GLU 40 144.379 75.621 96.995ATOM 391 N VAL 41 143.532 78.535 99.103ATOM 392 HN VAL 41 144.202 78.005 98.713ATOM 393 CA VAL 41 143.363 79.793 98.503ATOM 394 C VAL 41 144.596 80.539 98.178ATOM 395 O VAL 41 144.516 81.775 98.377ATOM 396 CB VAL 41 142.375 79.923 97.317ATOM 397 CG1 VAL 41 142.368 78.841 96.231ATOM 398 CG2 VAL 41 140.957 80.270 97.770ATOM 399 N LYS 42 145.710 79.974 97.706ATOM 400 HN LYS 42 145.715 79.035 97.677ATOM 401 CA LYS 42 146.854 80.649 97.263ATOM 402 C LYS 42 146.849 80.925 95.802ATOM 403 O LYS 42 147.573 80.280 94.982ATOM 404 CB LYS 42 148.078 79.949 97.878ATOM 405 CG LYS 42 149.294 80.876 97.933ATOM 406 CD LYS 42 150.150 80.498 99.147ATOM 407 CE LYS 42 151.389 81.388 99.301ATOM 408 NZ LYS 42 151.084 82.506 100.186ATOM 409 HNZ LYS 42 151.908 83.088 100.328ATOM 410 HNZ LYS 42 150.318 83.053 99.795ATOM 411 HNZ LYS 42 150.776 82.167 101.096ATOM 412 N ARG 43 146.029 81.891 95.391ATOM 413 HN ARG 43 145.563 82.360 96.057ATOM 414 CA ARG 43 145.783 82.270 94.067ATOM 415 C ARG 43 145.941 83.710 93.774ATOM 416 O ARG 43 146.565 83.966 92.700ATOM 417 CB ARG 43 144.493 81.593 93.565ATOM 418 CG ARG 43 144.667 80.731 92.296ATOM 419 CD ARG 43 145515 79.450 92.419ATOM 420 NE ARG 43 144.819 78.321 92.876ATOM 421 HNE ARG 43 144.190 77.961 92.276ATOM 422 CZ ARG 43 144.930 77.691 94.050ATOM 423 NH1 ARG 43 144.192 76.632 94.273ATOM 424 HNH1 ARG 43 144.241 76.238 95.125ATOM 425 HNH1 ARG 43 143.632 76.280 93.606ATOM 426 NH2 ARG 43 145.712 78.012 95.061ATOM 427 HNH2 ARG 43 145.667 77.548 95.875ATOM 428 HNH2 ARG 43 146.325 78.721 94.982ATOM 429 N ALA 44 145.479 84.678 94.591ATOM 430 HN ALA 44 144.962 84.425 95.333ATOM 431 CA ALA 44 145.688 86.067 94.498ATOM 432 C ALA 44 147.067 86.550 94.793ATOM 433 O ALA 44 147.221 87.612 95.453ATOM 434 CB ALA 44 144.968 86.688 93.286ATOM 435 N GLN 45 148.104 85.836 94.343ATOM 436 HN GLN 45 147.809 85.154 93.773ATOM 437 CA GLN 45 149.480 85.932 94.590ATOM 438 C GLN 45 150.316 85.364 93.497ATOM 439 O GLN 45 153.011 84.303 92.896ATOM 440 CB GLN 45 149.762 85.172 95.898ATOM 441 CG GLN 45 150.625 86.019 96.841ATOM 442 CD GLN 45 151.572 85.288 97.693ATOM 443 OE1 GLN 45 152.328 84.374 97.270ATOM 444 NE2 GLN 45 151.624 85.626 98.949ATOM 445 HNE2 GLN 45 152.224 85.197 99.531ATOM 446 HNE2 GLN 45 151.050 86.304 99.254ATOM 447 N ARG 46 151.447 85.846 93.006ATOM 448 HN ARG 46 151.822 85.346 92.303ATOM 449 CA ARG 46 152.162 86.988 93.377ATOM 450 C ARG 46 152.387 87.943 92.263ATOM 451 O ARG 46 152.662 87.539 91.100ATOM 452 CB ARG 46 153.510 86.577 93.996ATOM 453 CG ARG 46 153.509 86.947 95.480ATOM 454 CD ARG 46 154.910 87.056 96.087ATOM 455 NE ARG 46 154.850 87.323 97.461ATOM 456 HNE ARG 46 155.049 86.602 98.030ATOM 457 CZ ARG 46 154.554 88.453 98.107ATOM 458 NH1 ARG 46 154.699 88.390 99.405ATOM 459 HNH1 ARG 46 154.707 89.158 99.945ATOM 460 HNH1 ARG 46 154.795 87.541 99.797ATOM 461 NH2 ARG 46 154.136 89.600 97.608ATOM 462 HNH2 ARG 46 153.825 90.258 98.200ATOM 463 HNH2 ARG 46 154.137 89.749 96.679ATOM 464 N GLN 47 152.324 89.267 92.366ATOM 465 HN GLN 47 152.510 89.734 91.573ATOM 466 CA GLN 47 152.028 90.085 93.463ATOM 467 C GLN 47 153.123 90.713 94.230ATOM 468 O GLN 47 154.046 90.022 94.728ATOM 469 CB GLN 47 150.651 89.911 94.138ATOM 470 CG GLN 47 149.786 91.189 94.070ATOM 471 CD GLN 47 149.820 91.966 92.820ATOM 472 OE1 GLN 47 149.488 91.455 91.727ATOM 473 NE2 GLN 47 150.204 93.219 92.829ATOM 474 HNE1 GLN 47 150.365 93.652 92.011ATOM 475 HNE2 GLN 47 150.315 93.670 93.645ATOM 476 N VAL 48 153.051 92.037 94.339ATOM 477 HN VAL 48 152.248 92.413 94.027ATOM 478 CA VAL 48 153.971 92.965 94.834ATOM 479 C VAL 48 155.354 92.913 94.294ATOM 480 O VAL 48 156.266 92.335 94.928ATOM 481 CB VAL 48 153.623 93.614 96.196ATOM 482 CG1 VAL 48 154.471 93.214 97.409ATOM 483 CG2 VAL 48 153.630 95.144 96.091ATOM 484 N VAL 49 155.727 93.448 93.141ATOM 485 HN VAL 49 156.647 93.472 92.955ATOM 486 CA VAL 49 154.859 93.972 92.169ATOM 487 C VAL 49 154.543 92.972 91.137ATOM 488 O VAL 49 153.360 92.536 91.161ATOM 489 CB VAL 49 154.976 95.419 91.630ATOM 490 CG1 VAL 49 153.749 96.222 92.074ATOM 491 CG2 VAL 49 156.243 96.243 91.918ATOM 492 N ALA 50 155.463 92.564 90.258ATOM 493 HN ALA 50 156.289 93.012 90.277ATOM 494 CA ALA 50 155.333 91.538 89.318ATOM 495 C ALA 50 154.799 90.256 89.859ATOM 496 O ALA 5G 155.419 89.611 90.748ATOM 497 CB ALA 50 156.618 91.406 88.487ATOM 498 N GLY 51 153.653 89.700 89.479ATOM 499 HN GLY 51 153.370 88.950 89.968ATOM 500 CA GLY 51 152.818 90.108 88.442ATOM 501 C GLY 51 151.376 90.188 88.756ATOM 502 O GLY 51 150.762 89.134 89.039ATOM 503 N LEU 52 150.627 91.284 88.751ATOM 504 HN LEU 52 149.698 91.169 88.830ATOM 505 CA LEU 52 151.046 92.609 88.628ATOM 506 C LEU 52 150.248 93.585 89.404ATOM 507 O LEU 52 150.896 94.359 90.151ATOM 508 CB LEU 52 151.123 92.971 87.128ATOM 509 CG LEU 52 152.036 94.166 86.828ATOM 510 CD1 LEU 52 153.433 93.688 86.419ATOM 511 CD2 LEU 52 151.423 94.967 85.678ATOM 512 N ASN 53 148.917 93.641 89.309ATOM 513 HN ASN 53 148.488 92.853 89.028ATOM 514 CA ASN 53 148.093 94.745 89.564ATOM 515 C ASN 53 147.801 94.952 91.001ATOM 516 O ASN 53 148.401 95.900 91.567ATOM 517 CB ASN 53 146.845 94.727 88.642ATOM 518 CG ASN 53 147.036 94.581 87.190ATOM 519 OD1 ASN 53 147.042 95.597 86.463ATOM 520 ND2 ASN 53 147.198 93.396 86.645ATOM 521 HND2 ASN 53 147.254 93.301 85.711ATOM 522 HND2 ASN 53 147.261 92.645 87.206ATOM 523 N PHE 54 146.942 94.155 91.638ATOM 524 HN PHE 54 146.501 93.529 91.093ATOM 525 CA PHE 54 146.599 94.102 92.995ATOM 526 C PHE 54 146.374 92.721 93.494ATOM 527 O PHE 54 146.797 92.461 94.650ATOM 528 CB PHE 54 145.512 95.128 93.394ATOM 529 CG PHE 54 144.115 94.801 93.085ATOM 530 CD1 PHE 54 143.351 94.023 93.997ATOM 531 CD2 PHE 54 143.536 95.270 91.877ATOM 532 CE1 PHE 54 142.006 93.701 93.695ATOM 533 CE2 PHE 54 142.188 94.955 91.576ATOM 534 CZ PHE 54 141.435 94.169 92.485ATOM 535 N ARG 55 145.754 91.798 92.744ATOM 536 HN ARG 55 145.415 92.113 91.926ATOM 537 CA ARG 55 145.537 90.436 92.986ATOM 538 C ARG 55 144.580 90.132 94.084ATOM 539 O ARG 55 143.398 90.537 93.901ATOM 540 CB ARG 55 146.852 89.630 92.884ATOM 541 CG ARG 55 147.177 89.046 91.506ATOM 542 CD ARG 55 148.219 87.952 91.754ATOM 543 NE ARG 55 148.909 87.555 90.613ATOM 544 HNE ARG 55 149.460 88.186 90.187ATOM 545 CZ ARG 55 148.931 86.379 89.997ATOM 546 NH1 ARG 55 149.741 86.395 88.969ATOM 547 HNH1 ARG 55 149.875 85.643 88.421ATOM 548 HNH1 ARG 55 150.178 87.212 88.819ATOM 549 NH2 ARG 55 148.287 85.251 90.261ATOM 550 HNH2 ARG 55 148.379 84.530 89.665ATOM 551 HNH2 ARG 55 147.742 85.146 91.019ATOM 552 N ILE 56 144.925 89.465 95.192ATOM 553 HN ILE 56 145.765 89.043 95.207ATOM 554 CA ILE 56 144.194 89.281 96.368ATOM 555 C ILE 56 143.197 88.191 96.365ATOM 556 O ILE 56 142.189 88.235 95.611ATOM 557 CB ILE 56 143.948 90.562 97.211ATOM 558 CG1 ILE 56 144.230 90.343 98.706ATOM 559 CG2 ILE 56 142.570 91.23G 97.057ATOM 560 CD1 ILE 56 145.714 90.518 99.053ATOM 561 N THR 57 143.433 87.190 97.203ATOM 562 HN THR 57 144.297 87.119 97.566ATOM 563 CA THR 57 142.482 86.239 97.602ATOM 564 C THR 57 141.553 86.816 98.607ATOM 565 O THR 57 140.334 86.663 98.331ATOM 566 CB THR 57 142.965 84.799 97.906ATOM 567 OG1 THR 57 144.086 84.302 97.180ATOM 568 HOG1 THR 57 144.282 83.418 97.554ATOM 569 CG2 THR 57 141.857 83.778 97.629ATOM 570 N TYR 58 141.970 87.461 99.711ATOM 571 HN TYR 58 142.887 87.380 99.897ATOM 572 CA TYR 58 141.249 88.251 100.623ATOM 573 C TYR 58 140.469 87.500 101.632ATOM 574 O TYR 58 139.305 87.095 101.368ATOM 575 CB TYR 58 140.535 89.442 99.933ATOM 576 CC TYR 58 140.310 93.675 100.694ATOM 577 CD1 TYR 58 139.472 90.690 101.839ATOM 578 CD2 TYR 58 140.949 91.856 100.239ATOM 579 CE1 TYR 58 139.256 91.909 102.520ATOM 580 CE2 TYR 58 140.730 93.076 100.920ATOM 581 CZ TYR 58 139.884 93.087 102.054ATOM 582 OH TYR 58 139.669 94.246 102.713ATOM 583 HOH TYR 58 139.087 94.255 103.502ATOM 584 N SER 59 141.064 87.289 102.806ATOM 585 HN SER 59 141.931 87.641 102.891ATOM 586 CA SER 59 140.573 86.612 103.934ATOM 587 C SER 59 140.383 85.146 103.820ATOM 588 O SER 59 139.641 84.650 102.946ATOM 589 CB SER 59 139.450 87.337 104.691ATOM 590 OG SER 59 139.991 87.983 105.833ATOM 591 HOG SER 59 139.394 88.709 106.111ATOM 592 N ILE 60 140.959 84.231 104.585ATOM 593 HN ILE 60 140.688 83.342 104.446ATOM 594 CA ILE 60 141.930 84.432 105.577ATOM 595 C ILE 60 143.186 85.009 105.033ATOM 596 O ILE 60 143.506 86.114 105.526ATOM 597 CB ILE 60 142.188 83.299 106.612ATOM 598 CG1 ILE 60 141.262 82.065 106.678ATOM 599 CG2 ILE 60 142.180 83.923 108.012ATOM 600 CD1 ILE 60 141.691 80.932 105.738ATOM 601 N VAL 61 143.990 84.508 104.092ATOM 602 HN VAL 61 144.694 85.046 103.778ATOM 603 CA VAL 61 143.866 83.233 103.510ATOM 604 C VAL 61 144.933 82.321 103.997ATOM 605 C VAL 64 144.858 81.945 105.194ATOM 606 CB VAL 61 143.524 83.146 101.995ATOM 607 CG1 VAL 61 142.593 81.959 101.730ATOM 608 CC2 VAL 61 142.931 84.361 101.264ATOM 609 N GLN 62 145.991 81.806 103.388ATOM 610 HN GLN 62 146.626 81.425 103.968ATOM 611 CA GLN 62 146.321 81.715 102.032ATOM 612 C GLN 62 146.880 80.380 101.722ATOM 613 O GLN 62 146.326 79.756 100.784ATOM 614 CB GLN 62 147.141 82.893 101.478ATOM 615 CG GLN 62 146.653 83.199 100.050ATOM 616 CD GLN 62 147.488 84.000 99.146ATOM 617 OE1 GLN 62 148.739 83.998 99.205ATOM 618 NE2 GLN 62 146.910 84.742 98.230ATOM 619 HNE2 GLN 62 147.419 85.358 97.736ATOM 620 HNE2 GLN 62 145.991 84.661 98.053ATOM 621 N THR 63 147.908 79.862 102.406ATOM 622 HN THR 63 148.591 80.465 102.642ATOM 623 CA THR 63 148.058 78.522 102.813ATOM 624 C THR 63 146.903 78.038 103.616ATOM 625 O THR 63 145.751 77.930 103.110ATOM 626 CB THR 63 148.728 77.616 101.748ATOM 627 OG1 THR 63 150.084 78.024 101.556ATOM 628 HOG1 THR 63 150.436 78.356 102.407ATOM 629 CG2 THR 63 148.785 76.117 102.079ATOM 630 N ASN 64 147.124 77.730 104.886ATOM 631 HN ASN 64 148.006 77.524 105.135ATOM 632 CA ASN 64 146.171 77.688 105.911ATOM 633 C ASN 64 146.610 78.441 107.111ATOM 634 O ASN 64 145.853 79.364 107.496ATOM 635 CB ASN 64 145.574 76.288 106.179ATOM 636 CG ASN 64 144.288 76.067 105.498ATOM 637 OD1 ASN 64 143.234 76.594 105.928ATOM 638 ND2 ASN 64 144.231 75.312 104.425ATOM 639 HND2 ASN 64 143.435 75.247 103.928ATOM 640 HND2 ASN 64 144.993 74.836 104.149ATOM 641 N CYS 65 147.704 78.291 107.852ATOM 642 HN CYS 65 147.807 78.953 108.509ATOM 643 CA CYS 65 148.662 77.276 107.727ATOM 644 C CYS 65 149.755 77.580 106.785ATOM 645 D CYS 65 149.757 76.878 105.740ATOM 646 CB CYS 65 149.191 76.684 109.046ATOM 647 SG CYS 65 147.981 75.852 110.043ATOM 648 N SEH 66 150.671 78.523 107.023ATOM 649 CA SER 66 151.821 78.916 106.322ATOM 650 C SER 66 151.618 79.632 105.048ATOM 651 O SEB 66 151.071 79.038 104.073ATOM 652 CB SER 66 152.894 77.809 106.255ATOM 653 OG SER 66 154.197 78.343 106.052ATOM 654 HOG SER 66 154.439 78.916 106.808ATOM 655 N LYS 67 152.041 80.894 105.003ATOM 656 HN LYS 67 152.283 81.307 105.813ATOM 657 CA LYS 67 152.161 81.641 103.831ATOM 658 C LYS 67 150.997 82.423 103.368ATOM 659 O LYS 67 150.085 81.740 102.848ATOM 660 CB LYS 67 153.576 82.179 103.596ATOM 661 CG LYS 67 154.216 81.366 102.467ATOM 662 CD LYS 67 155.545 82.014 102.087ATOM 663 CE LYS 67 155.734 82.000 100.571ATOM 664 NZ LYS 67 156.348 83.253 100.145ATOM 665 HNZ1 LYS 67 155.739 84.042 100.354ATOM 666 HNZ2 LYS 67 156.498 83.219 99.137ATOM 667 HNZ3 LYS 67 157.253 83.335 100.607ATOM 668 N GLU 68 150.729 83.723 103.389ATOM 669 HN GLU 68 149.913 83.970 102.992ATOM 670 CA GLU 68 151.484 84.770 103.918ATOM 671 C GLU 68 150.720 85.384 105.031ATOM 672 O GLU 68 151.049 85.037 106.183ATOM 673 CB GLU 68 151.934 85.753 102.816ATOM 674 CG GLU 68 153.444 85.722 102.523ATOM 675 CD GLU 68 153.843 85.175 101.220ATOM 676 OE1 GLU 68 154.693 85.730 100.495ATOM 677 OE2 GLU 68 153.381 84.119 100.743ATOM 678 N ASN 69 149.711 86.252 105.036ATOM 679 HN ASN 69 149.369 86.472 105.883ATOM 680 CA ASN 69 149.084 86.887 103.962ATOM 681 C ASN 69 148.395 88.127 104.368ATOM 682 O ASN 69 148.699 89.117 103.652ATOM 683 CB ASN 69 148.284 85.932 103.035ATOM 684 CG ASN 69 147.082 86.406 102.339ATOM 685 OD1 ASN 69 145.976 86.180 102.865ATOM 686 ND2 ASN 69 147.125 87.046 101.194ATOM 687 HND2 ASN 69 146.325 87.336 100.795ATOM 688 HND2 ASN 69 147.945 87.217 100.769ATOM 689 N PHE 70 147.526 88.206 105.387ATOM 690 HN PHE 70 147.501 87.547 106.055ATOM 691 CA PHE 70 146.599 89.228 105.544ATOM 692 C PHE 70 146.632 89.940 106.840ATOM 693 O PHE 70 147.156 91.065 106.791ATOM 694 CB PHE 70 145.252 88.698 105.035ATOM 695 CG PHE 70 144.386 89.689 104.407ATOM 696 CD1 PHE 70 143.280 90.188 105.138ATOM 697 CD2 PHE 70 144.651 90.131 103.084ATOM 698 CE1 PHE 70 142.418 91.137 104.542ATOM 699 CE2 PHE 70 143.798 91.088 102.487ATOM 700 CZ PHE 70 142.694 91.579 103.226ATOM 701 N LEU 71 146.212 89.628 108.060ATOM 702 HN LEU 71 146.378 90.285 108.710ATOM 703 CA LEU 71 145.565 88.489 108.541ATOM 704 C LEU 71 146.377 87.305 108.854ATOM 705 C LEU 71 147.034 86.694 107.961ATOM 706 CB LEU 71 144.125 88.221 108.061ATOM 707 CG LEU 71 143.093 88.581 109.134ATOM 708 CD1 LEU 71 141.981 89.429 108.512ATOM 709 CD2 LEU 71 142.479 87.306 109.717ATOM 710 N PHE 72 146.333 86.971 110.140ATOM 711 HN PHE 72 145.821 87.541 110.685ATOM 712 CA PHE 72 146.932 85.896 110.795ATOM 713 C PHE 72 146.780 84.582 110.141ATOM 714 O PHE 72 145.649 84.077 109.873ATOM 715 CB PHE 72 146.445 85.920 112.258ATOM 716 CG PHE 72 147.494 86.159 113.257ATOM 717 CD1 PHE 72 148.218 87.382 113.299ATOM 718 CD2 PHE 72 147.771 85.134 114.197ATOM 719 CE1 PHE 72 149.223 87.574 114.279ATOM 720 CE2 PHE 72 148.776 85.318 115.177ATOM 721 CZ PHE 72 149.495 86.539 11.208ATOM 722 N LEU 73 147.921 83.972 109.848ATOM 723 HN LEU 73 148.717 84.370 110.150ATOM 724 CA LEU 73 148.059 82.791 109.123ATOM 725 C LEU 73 148.400 81.544 109.826ATOM 726 O LEU 73 147.650 80.580 109.584ATOM 727 CB LEU 73 148.827 82.985 107.810ATOM 728 CG LEU 73 147.883 82.573 106.679ATOM 729 CD1 LEU 73 147.537 83.802 105.841ATOM 730 CD2 LEU 73 148.527 81.482 105.825ATOM 731 N THR 74 149.352 81.219 110.674ATOM 732 HN THR 74 149.319 80.317 110.933ATOM 733 CA THR 74 150.401 81.900 111.284ATOM 734 C THR 74 151.463 80.918 111.604ATOM 735 O THR 74 151.431 80.644 112.832ATOM 736 CB THR 74 150.691 83.386 110.992ATOM 737 OG1 THR 74 151.586 83.721 109.943ATOM 738 HOG1 THR 74 152.518 83.590 110.218ATOM 739 CG2 THR 74 150.935 84.192 112.269ATOM 740 N PRO 75 152.352 80.337 110.765ATOM 741 CA PRO 75 153.177 79.236 111.069ATOM 742 C PRO 75 153.942 79.230 112.342ATOM 743 O PRO 75 154.808 80.109 112.571ATOM 744 CB PRO 75 154.043 78.927 109.841ATOM 745 CG PRO 75 153.912 80.191 109.000ATOM 746 CD PRO 75 152.562 80.744 109.449ATOM 747 N ASP 76 153.777 78.332 113.308ATOM 748 HN ASP 76 154.317 78.422 114.072ATOM 749 CA ASP 76 152.879 77.264 113.298ATOM 750 C ASP 76 151.892 77.153 114.404ATOM 751 C ASP 76 152.226 77.243 115.615ATOM 752 CB ASP 76 153.632 75.954 113.016ATOM 753 CG ASP 76 152.785 75.113 112.176ATOM 754 OD1 ASP 76 152.210 74.123 112.674ATOM 755 OD2 ASP 76 152.636 75.398 110.967ATOM 756 N CYS 77 150.592 76.950 114.225ATOM 757 HN CYS 77 150.075 76.854 115.004ATOM 758 CA CYS 77 149.896 76.871 113.013ATOM 759 C CYS 77 149.130 78.089 112.682ATOM 760 O CYS 77 149.282 78.516 111.513ATOM 761 CB CYS 77 149.013 75.611 112.961ATOM 762 SG CYS 77 149.064 74.805 111.379ATOM 763 N LYS 78 148.334 78.707 113.555ATOM 764 HN LYS 78 148.257 78.358 114.423ATOM 765 CA LYS 78 147.578 79.851 113.363ATOM 766 C LYS 78 148.088 81.062 114.048ATOM 767 O LYS 78 147.870 82.112 113.403ATOM 768 CB LYS 78 146.083 79.531 113.572ATOM 769 CG LYS 78 145.105 80.415 112.775ATOM 770 CD LYS 78 145.103 80.116 111.269ATOM 771 CE LYS 78 144.036 80.927 110.528ATOM 772 NZ LYS 78 144.491 81.430 109.229ATOM 773 HNZ LYS 78 145.049 80.741 108.728ATOM 774 HNZ LYS 78 143.669 81.647 108.667ATOM 775 HNZ LYS 78 145.000 82.299 109.394ATOM 776 N SER 79 148.729 81.304 115.196ATOM 777 HN SER 79 148.836 82.226 115.344ATOM 778 CA SER 79 149.292 80.544 116.241ATOM 779 C SER 79 150.658 80.996 116.572ATOM 780 O SER 79 150.797 81.466 117.732ATOM 781 CB SER 79 149.158 79.022 116.458ATOM 782 OG SER 79 147.823 78.550 116.591ATOM 783 HOG SER 79 147.325 78.723 115.765ATOM 784 N LEU 80 151.668 80.922 115.703ATOM 785 CA LEU 80 152.963 81.431 115.833ATOM 786 C LEU 80 153.247 82.594 114.957ATOM 787 O LEU 80 152.762 83.663 115.416ATOM 788 CB LEU 80 153.999 80.296 115.934ATOM 789 CG LEU 80 155.297 80.733 116.619ATOM 790 CD1 LEU 80 155.485 79.940 117.913ATOM 791 CD2 LEU 80 156.484 80.469 115.689ATOM 792 N TRP 81 153.935 82.560 113.803ATOM 793 HN TRP 81 154.226 81.723 113.492ATOM 794 CA TRP 81 154.290 83.629 112.961ATOM 795 C TRP 81 154.985 83.254 111.709ATOM 796 O TRP 81 154.324 83.406 110.650ATOM 797 CB TRP 81 154.962 84.854 113.625ATOM 798 CG TRP 81 154.110 86.054 113.634ATOM 799 CD1 TRP 81 153.770 86.758 114.792ATOM 800 CD2 TRP 81 153.492 86.724 112.578ATOM 801 NE1 TRP 81 152.996 87.772 114.453ATOM 802 HNE1 TRP 81 152.634 88.391 115.059ATOM 803 CE2 TRP 81 152.799 87.796 113.157ATOM 804 CE3 TRP 81 153.466 86.500 111.179ATOM 805 CZ2 TRP 81 152.039 88.700 112.378ATOM 806 CZ3 TRP 81 152.687 87.383 110.391ATOM 807 CH2 TRP 81 151.989 88.471 110.979ATOM 808 N ASN 82 156.237 82.793 111.687ATOM 809 HN ASN 82 156.556 82.385 112.473ATOM 810 CA ASN 82 157.126 82.884 110.614ATOM 811 C ASN 82 157.270 81.778 109.638ATOM 812 O ASN 82 157.334 80.570 110.006ATOM 813 CB ASN 82 158.455 83.363 111.227ATOM 814 CG ASN 82 159.240 84.228 110.346ATOM 815 OD1 ASN 82 160.047 83.703 109.548ATOM 816 ND2 ASN 82 159.123 85.532 110.380ATOM 817 HND2 ASN 82 159.677 86.063 109.838ATOM 818 HND2 ASN 82 158.489 85.940 110.941ATOM 819 N GLY 83 157.333 82.163 108.368ATOM 820 HN GLY 83 157.189 83.081 108.229ATOM 821 CA GLY 83 157.593 81.402 107.223ATOM 822 C GLY 83 157.453 82.153 105.965ATOM 823 O GLY 83 156.517 81.783 105.215ATOM 824 N ASP 84 158.292 83.151 105.690ATOM 825 HN ASP 84 158.966 83.290 106.330ATOM 826 CA ASP 84 158.327 84.030 104.599ATOM 827 C ASP 84 157.071 84.644 104.065ATOM 828 O ASP 84 156.934 84.881 102.842ATOM 829 CB ASP 84 159.460 83.592 103.633ATOM 830 CG ASP 84 159.065 82.772 102.480ATOM 831 OD1 ASP 84 158.775 81.563 102.610ATOM 832 OD2 ASP 84 159.000 83.272 101.332ATOM 833 N THR 85 155.968 85.038 104.691ATOM 834 HN THR 85 155.241 85.195 104.116ATOM 835 CA THR 85 155.688 85.277 106.038ATOM 836 C THR 85 156.732 85.670 107.005ATOM 837 O THR 85 156.919 84.955 108.026ATOM 838 CB THR 85 154.321 84.728 106.495ATOM 839 OG1 THR 85 153.584 85.638 107.295ATOM 840 HOG1 THR 85 152.657 85.503 107.007ATOM 841 CG2 THR 85 154.257 83.338 107.135ATOM 842 N GLY 86 157.413 86.782 106.731ATOM 843 HN GLY 86 157.232 87.193 105.906ATOM 844 CA GLY 86 158.352 87.401 107.565ATOM 845 C GLY 86 157.747 88.498 108.336ATOM 846 O GLY 86 158.299 89.617 108.225ATOM 847 N GLU 87 156.669 88.255 109.081ATOM 848 HN GLU 87 156.510 87.344 109.245ATOM 849 CA GLU 87 155.740 89.152 109.626ATOM 850 C GLU 87 155.027 89.915 108.574ATOM 851 O GLU 87 155.381 91.084 108.241ATOM 852 CB GLU 87 156.205 89.875 110.909ATOM 853 CG GLU 87 156.184 88.984 112.169ATOM 854 CD GLU 87 157.244 87.969 112.233ATOM 855 OE1 GLU 87 158.410 88.288 112.548ATOM 856 OE2 GLU 87 157.011 86.765 111.977ATOM 857 N CYS 88 154.009 89.267 108.005ATOM 858 HN CYS 88 153.741 88.467 108.420ATOM 859 CA CYS 88 153.301 89.623 106.858ATOM 860 C CYS 88 153.989 89.205 105.618ATOM 861 O CYS 88 154.073 87.983 105.292ATOM 862 CB CYS 88 151.854 89.101 106.933ATOM 863 SG CYS 88 150.624 90.247 106.369ATOM 864 N THR 89 154.496 90.187 104.876ATOM 865 HN THR 89 154.350 91.058 105.196ATOM 866 CA THR 89 155.214 90.104 103.666ATOM 867 C THR 89 154.446 90.143 102.397ATOM 868 O THR 89 155.036 90.711 101.431ATOM 869 CB THR 89 156.604 89.413 103.603ATOM 870 OG1 THR 89 156.679 88.129 104.203ATOM 871 HOG1 THR 89 155.801 87.995 104.616ATOM 872 CG2 THR 89 157.715 90.301 104.177ATOM 873 N ASP 90 153.208 89.634 102.253ATOM 874 HN ASP 90 152.869 89.166 102.993ATOM 875 CA ASP 90 152.377 89.739 101.120ATOM 876 C ASP 90 152.208 91.108 100.589ATOM 877 O ASP 90 152.789 91.327 99.489ATOM 878 CB ASP 90 151.100 88.866 101.133ATOM 879 CG ASP 90 150.519 88.478 99.830ATOM 880 OD1 ASP 90 149.629 87.593 99.796ATOM 881 OD2 ASP 90 150.856 88.973 98.725ATOM 882 N ASN 91 151.512 92.063 101.220ATOM 883 HN ASN 91 151.051 91.792 101.992ATOM 884 CA ASN 91 151.401 93.430 100.874ATOM 885 C ASN 91 150.555 93.783 99.706ATOM 886 O ASN 91 149.669 94.659 99.892ATOM 887 CB ASN 91 152.754 94.193 100.912ATOM 888 CG ASN 91 153.345 94.302 102.252ATOM 889 OD1 ASN 91 152.205 94.369 102.889ATOM 890 ND1 ASN 91 154.009 93.310 102.800ATOM 891 HND2 ASN 91 154.181 93.321 103.723ATOM 892 HND2 ASN 91 154.307 92.578 102.293ATOM 893 N ALA 92 150.759 93.176 98.534ATOM 894 HN ALA 92 151.471 92.570 98.601ATOM 895 CA ALA 92 150.103 93.281 97.295ATOM 896 C ALA 92 149.921 94.579 96.593ATOM 897 O ALA 92 150.325 94.645 95.403ATOM 898 CB ALA 92 148.849 92.387 97.308ATOM 899 N TYR 93 149.348 95.601 97.224ATOM 900 HN TYR 93 149.366 95.451 98.150ATOM 901 CA TYR 93 148.741 96.785 96.772ATOM 902 C TYR 93 149.462 97.745 94.920ATOM 903 O TYR 93 149.765 97.489 94.723ATOM 904 CB TYR 93 147.264 96.603 96.350ATOM 905 CG TYR 93 146.370 95.969 97.328ATOM 906 CD1 TYR 93 145.733 94.761 96.949ATOM 907 CD2 TYR 93 146.148 96.547 98.606ATOM 908 CE1 TYR 93 144.845 94.130 97.848ATOM 909 CE2 TYR 93 145.262 95.915 99.509ATOM 910 CZ TYR 93 144.614 94.721 99.112ATOM 911 OH TYR 93 143.747 94.130 99.959ATOM 912 HOH TYR 93 143.565 94.525 100.837ATOM 913 N ILE 94 149.756 98.919 96.482ATOM 914 HN ILE 94 149.402 99.092 97.335ATOM 915 CA ILE 94 150.534 99.957 95.948ATOM 916 C ILE 94 149.917 101.262 96.248ATOM 917 O ILE 94 150.194 101.883 97.314ATOM 918 CB ILE 94 152.085 99.896 96.085ATOM 919 CG1 ILE 94 152.748 98.993 95.032ATOM 920 CG1 ILE 94 152.668 99.576 97.476ATOM 921 CD1 ILE 94 153.137 99.769 93.767ATOM 922 N ASP 95 149.066 101.712 95.332ATOM 923 HN ASP 95 148.995 101.217 94.537ATOM 924 CA ASP 95 148.265 102.846 95.441ATOM 925 C ASP 95 146.824 102.536 95.321ATOM 926 O ASP 95 146.172 102.507 96.400ATOM 927 CB ASP 95 148.825 103.952 84.526ATOM 928 CG ASP 95 148.113 105.218 94.678ATOM 929 OD1 ASP 95 147.244 105.528 93.840ATOM 930 OD2 ASP 95 148.363 105.986 95.629ATOM 931 N ILE 96 146.248 102.299 94.143ATOM 932 CA ILE 96 144.898 102.039 93.908ATOM 933 C ILE 96 144.226 103.067 93.065ATOM 934 O ILE 96 143.980 102.868 91.850ATOM 935 CB ILE 96 144.612 100.523 93.754ATOM 936 CG1 ILE 96 145.057 99.868 92.434ATOM 937 CG2 ILE 96 143.159 100.158 94.090ATOM 938 CD1 ILE 96 146.334 99.039 92.623ATOM 939 N GLN 97 143.829 104.258 93.505ATOM 940 HN GLN 97 143.387 104.809 92.885ATOM 941 CA GLN 97 143.998 104.780 94.790ATOM 942 C GLN 97 143.014 104.307 95.786ATOM 943 O GLN 97 141.790 104.611 95.697ATOM 944 CB GLN 97 144.161 106.313 94.726ATOM 945 CG GLN 97 144.815 106.875 96.003ATOM 946 CD GLN 97 145.375 108.223 85.870ATOM 947 OE1 GLN 97 144.640 109.236 95.947ATOM 948 NE2 GLN 97 146.662 108.375 95.675ATOM 949 HNE2 GLN 97 147.035 109.234 95.596ATOM 950 HNE2 GLN 97 147.208 107.614 95.617ATOM 951 N LEU 98 143.516 103.555 96.759ATOM 952 HN LEU 98 144.402 103.266 96.640ATOM 953 CA LEU 98 142.909 103.129 97.944ATOM 954 C LEU 98 142.159 101.854 97.878ATOM 955 O LEU 98 141.190 101.697 97.099ATOM 956 CB LEU 98 142.286 104.211 98.851ATOM 957 CG LEU 98 143.338 104.851 99.766ATOM 958 CD1 LEU 98 143.135 106.367 99.802ATOM 959 CD2 LEU 98 143.224 104.290 101.186ATOM 960 N ARG 99 142.443 100.793 98.623ATOM 961 HN ARG 99 141.935 100.017 98.465ATOM 962 CA ARG 99 143.420 100.718 99.624ATOM 963 C ARG 99 144.819 100.550 99.185ATOM 964 O ARG 99 145.141 99.620 98.398ATOM 965 CB ARG 99 143.003 99.861 100.839ATOM 966 CG ARG 99 142.869 98.341 100.628ATOM 967 CD ARG 99 141.410 97.867 100.691ATOM 968 NE ARG 99 140.989 97.709 102.013ATOM 969 HNE ARG 99 141.653 97.644 102.674ATOM 970 CZ ARG 99 139.772 97.636 102.530ATOM 971 NH1 ARG 99 139.803 97.517 103.830ATOM 972 HNH1 ARG 99 139.026 97.442 104.351ATOM 973 HNH1 ARG 99 140.663 97.510 104.204ATOM 974 NH2 ARG 99 138.600 97.673 101.923ATOM 975 HNH2 ARG 99 137.807 97.616 102.426ATOM 976 HNH2 ARG 99 138.557 97.753 100.987ATOM 977 N ILE 100 145.682 101.433 99.675ATOM 978 HN ILE 100 145.314 102.111 100.212ATOM 979 CA ILE 100 147.072 101.483 99.498ATOM 980 C ILE 100 147.792 100.222 99.817ATOM 981 O ILE 100 148.526 99.739 98.920ATOM 982 CB ILE 100 147.570 102.841 100.071ATOM 983 CG1 ILE 100 147.944 103.824 98.952ATOM 984 CG2 ILE 100 148.696 102.853 101.124ATOM 985 CD1 ILE 100 146.881 104.912 98.756ATOM 986 N ALA 101 147.661 99.627 101.003ATOM 987 HN ALA 101 147.091 100.056 101.614ATOM 988 CA ALA 101 148.270 98.441 101.434ATOM 989 C ALA 101 147.547 97.789 102.547ATOM 990 O ALA 101 147.144 96.617 102.376ATOM 991 CB ALA 101 149.777 98.582 101.740ATOM 992 N SER 102 147.265 98.299 103.740ATOM 993 HN SER 102 147.120 97.697 104.445ATOM 994 CA SER 102 147.160 99.656 104.067ATOM 995 C SER 102 145.802 100.170 103.755ATOM 996 O SER 102 145.736 101.035 102.849ATOM 997 CB SER 102 147.655 100.097 105.466ATOM 998 OG SER 102 148.444 99.184 106.224ATOM 999 HOG SER 102 148.024 98.299 106.179ATOM 1000 N PHE 103 144.645 99.813 104.321ATOM 1001 HN PHE 103 143.868 100.265 104.043ATOM 1002 CA PHE 103 144.500 98.816 105.291ATOM 1003 C PHE 103 143.856 97.568 104.840ATOM 1004 O PHE 103 142.701 97.585 104.324ATOM 1005 CB PHE 103 143.928 99.360 106.615ATOM 1006 CG PHE 103 144.623 98.770 107.764ATOM 1007 CD1 PHE 103 145.691 99.485 108.365ATOM 1008 CD2 PHE 103 144.236 97.498 107.267ATOM 1009 CE1 PHE 103 146.399 98.915 109.450ATOM 1010 CE2 PHE 103 144.943 96.924 109.351ATOM 1011 CZ PHE 103 146.021 97.637 109.931ATOM 1012 N SER 104 144.549 96.448 105.009ATOM 1013 HN SER 104 145.426 96.529 105.340ATOM 1014 CA SER 104 144.122 95.141 104.755ATOM 1015 C SER 104 144.594 94.151 105.745ATOM 1016 O SER 104 143.674 93.550 106.351ATOM 1017 CB SER 104 144.242 94.709 103.282ATOM 1018 OG SER 104 143.171 95.296 102.556ATOM 1019 HOG SER 104 142.941 96.103 103.062ATOM 1020 N GLN 105 145.837 93.800 106.090ATOM 1021 HN GLN 105 145.895 93.152 106.766ATOM 1022 CA GLN 105 147.094 94.214 105.613ATOM 1023 C GLN 105 147.734 95.447 106.130ATOM 1024 O GLN 105 147.189 96.579 106.014ATOM 1025 CB GLN 105 147.418 93.961 104.123ATOM 1026 CG GLN 105 147.266 92.511 103.622ATOM 1027 CD GLN 105 147.426 92.297 102.176ATOM 1028 OE1 GLN 105 146.975 93.077 101.302ATOM 1029 NE2 GLN 105 148.065 91.232 101.764ATOM 1030 HNE2 GLN 105 148.258 91.122 100.851ATOM 1031 HNE2 GLN 105 148.326 90.576 102.385ATOM 1032 N ASN 106 148.915 95.283 106.708ATOM 1033 HN ASN 106 149.083 94.431 107.067ATOM 1034 CA ASN 106 149.953 96.206 106.849ATOM 1035 C ASN 106 150.978 96.087 105.777ATOM 1036 O ASN 106 151.210 97.149 105.153ATOM 1037 CB ASN 106 150.581 96.139 108.253ATOM 1038 CG ASN 106 149.859 96.820 109.329ATOM 1039 OD1 ASN 106 149.881 98.068 109.424ATOM 1040 ND2 ASN 106 149.192 96.109 110.202ATOM 1041 HND2 ASN 106 148.711 96.531 110.889ATOM 1042 HND2 ASN 106 149.204 95.171 110.138ATOM 1043 N CYS 107 151.686 95.024 105.371ATOM 1044 HN CYS 107 152.252 95.157 104.633ATOM 1045 CA CYS 107 151.657 93.734 105.912ATOM 1046 C CYS 107 152.925 93.171 106.457ATOM 1047 O CYS 107 153.917 92.916 105.722ATOM 1048 CB CYS 107 150.887 92.885 104.872ATOM 1049 SG CYS 107 151.233 91.155 104.681ATOM 1050 N ASP 108 153.149 92.867 107.732ATOM 1051 HN ASP 108 153.907 92.337 107.894ATOM 1052 CA ASP 108 152.423 93.222 108.872ATOM 1053 C ASP 108 153.368 93.438 110.005ATOM 1054 O ASP 108 153.744 92.498 110.758ATOM 1055 CB ASP 108 151.290 92.211 109.165ATOM 1056 CG ASP 108 149.939 92.758 109.033ATOM 1057 OD1 ASP 108 149.319 93.200 110.023ATOM 1058 OD2 ASP 108 149.381 92.790 107.923ATOM 1059 N ILE 109 153.912 94.601 110.341ATOM 1060 HN ILE 109 154.497 94.585 111.076ATOM 1061 CA ILE 109 153.720 95.851 109.727ATOM 1062 C ILE 109 154.399 96.036 108.429ATOM 1063 O ILE 109 153.757 96.519 107.470ATOM 1064 CB ILE 109 153.887 97.105 110.629ATOM 1065 CG1 ILE 109 155.198 97.234 111.428ATOM 1066 CG2 ILE 109 152.681 97.347 111.549ATOM 1067 CD1 ILE 109 156.158 98.237 110.776ATOM 1068 OXT GLN 109 155.598 95.737 108.216CONECT 1 5 2 3 4CONECT 2 1CONECT 3 1CONECT 4 1CONECT 5 1 6 8CONECT 6 7 5 10CONECT 7 6CONECT 8 9 5CONECT 9 8 30CONECT 10 12 6 11CONECT 11 10CONECT 12 10 13 15CONECT 13 12 14 19CONECT 14 13CONECT 15 16 12CONECT 16 15 17 18CONECT 17 16CONECT 18 16CONECT 19 20 21 13CONECT 20 19CONECT 21 19 22CONECT 22 21 23 24CONECT 23 22CONECT 24 26 22 25CONECT 25 24CONECT 26 24 27 29CONECT 27 28 26 31CONECT 28 17CONECT 29 30 26CONECT 30 29 9CONECT 31 32 27CONECT 32 31 33 35CONECT 33 34 32 38CONECT 34 33CONECT 35 36 37 32CONECT 36 35CONECT 37 35CONECT 38 33 40 39CONECT 39 38CONECT 40 38 41 43CONECT 41 42 40 50CONECT 42 41CONECT 43 44 40CONECT 44 43 45 47CONECT 45 44 48 46CONECT 46 45CONECT 47 44 49CONECT 48 45 49CONECT 49 47 48CONECT 50 51 41 56CONECT 51 50 52 54CONECT 52 53 51 57CONECT 53 52CONECT 54 55 51CONECT 55 54 56CONECT 56 55 50CONECT 57 52 59 58CONECT 58 57CONECT 59 57 60 62CONECT 60 61 59 66CONECT 61 60CONECT 62 63 64 59CONECT 63 62 65CONECT 64 62CONECT 65 63CONECT 66 60 68 67CONECT 67 66CONECT 68 66 69 71CONECT 69 70 68 74CONECT 70 69CONECT 71 72 68CONECT 72 71 73CONECT 73 72CONECT 74 69 76 75CONECT 75 74CONECT 76 74 77 79CONECT 77 78 76 83CONECT 78 77CONECT 79 80 82 76CONECT 80 79 81CONECT 81 80CONECT 82 79CONECT 83 77 85 84CONECT 84 83CONECT 85 83 86 88CONECT 86 87 85 95CONECT 87 86CONECT 88 89 85CONECT 89 88 90CONECT 90 89 91 92CONECT 91 90CONECT 92 90 93 94CONECT 93 92CONECT 94 92CONECT 95 86 97 95CONECT 96 95CONECT 97 95 98 100CONECT 98 99 97 103CONECT 99 98CONECT 100 101 97CONECT 101 100 102CONECT 102 101CONECT 103 98 104 109CONECT 104 103 105 107CONECT 105 106 104 110CONECT 106 105CONECT 107 108 104CONECT 108 107 109CONECT 109 108 103CONECT 110 105 112 111CONECT 111 110CONECT 112 110 113 115CONECT 113 114 112 119CONECT 114 113CONECT 115 116 112CONECT 116 115 117 118CONECT 117 116CONECT 118 116CONECT 119 113 121 120CONECT 120 119CONECT 121 124 119 122CONECT 122 123 121 128CONECT 123 122CONECT 124 121 125CONECT 125 124 126 127CONECT 126 125CONECT 127 125CONECT 128 122 130 129CONECT 129 128CONECT 130 128 131 133CONECT 131 132 130 138CONECT 132 131CONECT 133 134 130CONECT 134 133 135CONECT 135 134 136 137CONECT 136 135CONECT 137 135CONECT 138 131 139 144CONECT 139 138 140 142CONECT 140 141 139 145CONECT 141 140CONECT 142 143 139CONECT 143 142 144CONECT 144 143 138CONECT 145 140 147 146CONECT 146 145CONECT 147 145 148 150CONECT 148 149 147 154CONECT 149 148CONECT 150 151 152 147CONECT 151 150 153CONECT 152 150CONECT 153 151CONECT 154 148 156 155CONECT 155 154CONECT 156 159 154 157CONECT 157 158 156 164CONECT 158 157CONECT 159 156 160CONECT 160 159 161 162CONECT 161 160CONECT 162 160CONECT 163 147 165 164CONECT 164 163CONECT 165 163 166 168CONECT 166 167 165 180CONECT 167 166CONECT 168 169 164CONECT 169 168 170CONECT 170 169 171CONECT 171 170 173 172CONECT 172 171CONECT 173 171 174 177CONECT 174 173 175 176CONECT 175 174CONECT 176 174CONECT 177 173 178 179CONECT 178 177CONECT 179 177CONECT 180 166 182 181CONECT 181 180CONECT 182 180 183 185CONECT 183 184 182 192CONECT 184 183CONECT 185 186 182CONECT 186 185 187 189CONECT 187 186 190 188CONECT 188 187CONECT 189 186 191CONECT 190 187 191CONECT 191 189 190CONECT 192 183 194 193CONECT 193 192CONECT 194 192 195CONECT 195 196 194 197CONECT 196 195CONECT 197 195 199 198CONECT 198 197CONECT 199 197 200 202CONECT 200 201 199 206CONECT 201 200CONECT 202 203 204 199CONECT 203 202 205CONECT 204 202CONECT 205 203CONECT 206 200 208 207CONECT 207 206CONECT 208 206 209 211CONECT 209 210 208 218CONECT 210 209CONECT 211 212 208CONECT 212 211 213CONECT 213 212 214 215CONECT 214 213CONECT 215 213 216 217CONECT 216 215CONECT 217 215CONECT 218 209 220 219CONECT 219 218CONECT 220 218 221 223CONECT 221 222 220 232CONECT 222 221CONECT 223 224 220CONECT 224 223 225 226CONECT 225 224 227CONECT 226 224 228CONECT 227 225 229CONECT 228 226 229CONECT 229 227 228 230CONECT 230 229 231CONECT 231 230CONECT 232 221 234 233CONECT 233 232CONECT 234 232 235 237CONECT 235 236 234 244CONECT 236 235CONECT 237 238 234CONECT 238 237 239 240CONECT 239 238 241CONECT 240 238 242CONECT 241 239 243CONECT 242 240 243CONECT 243 241 242CONECT 244 235 246 245CONECT 245 244CONECT 246 249 244 247CONECT 247 248 246 255CONECT 248 247CONECT 249 246 250CONECT 250 249 251 252CONECT 251 250CONECT 252 250 254 253CONECT 253 252CONECT 254 252CONECT 255 247 257 256CONECT 256 255CONECT 257 255 258 260CONECT 258 259 257 266CONECT 259 258CONECT 260 261 257CONECT 261 260 262 263CONECT 262 261CONECT 263 261 264 265CONECT 264 263CONECT 265 263CONECT 266 258 268 267CONECT 267 266CONECT 268 266 269 271CONECT 269 270 268 277CONECT 270 269CONECT 271 272 268CONECT 272 271 273 274CONECT 273 272CONECT 274 272 275 276CONECT 275 274CONECT 276 274CONECT 277 269 279 278CONECT 278 277CONECT 279 277 280 282CONECT 280 281 279 286CONECT 281 280CONECT 282 283 285 279CONECT 283 282 284CONECT 284 283CONECT 285 282CONECT 286 280 288 287CONECT 287 286CONECT 288 286 289 291CONECT 289 290 288 298CONECT 290 289CONECT 291 292 288CONECT 292 291 293CONECT 293 292 294 295CONECT 294 293CONECT 295 293 296 297CONECT 296 295CONECT 297 295CONECT 298 289 399 299CONECT 299 298CONECT 300 298 301 303CONECT 301 302 300 310CONECT 302 301CONECT 303 304 300CONECT 304 303 305 307CONECT 305 304 308 306CONECT 306 305CONECT 307 304 309CONECT 308 305 309CONECT 309 307 308CONECT 310 301 312 311CONECT 311 310CONECT 312 310 313 315CONECT 313 314 312 318CONECT 314 313CONECT 315 316 312CONECT 316 315 317CONECT 317 316CONECT 318 313 320 319CONECT 319 318CONECT 320 318 321 323CONECT 321 322 320 326CONECT 322 321CONECT 323 324 320CONECT 324 323 325CONECT 325 324CONECT 326 321 328 327CONECT 327 326CONECT 328 326 329 331CONECT 329 330 328 340CONECT 330 329CONECT 331 332 328CONECT 332 331 333 334CONECT 333 332 335CONECT 334 332 336CONECT 335 333 337CONECT 336 334 337CONECT 337 335 337 338CONECT 338 337 339CONECT 339 338CONECT 340 329 342 341CONECT 341 340CONECT 342 340 343 345CONECT 343 344 342 352CONECT 344 343CONECT 345 346 342CONECT 346 345 347 348CONECT 347 346 349CONECT 348 346 350CONECT 349 347 351CONECT 350 348 351CONECT 351 349 350CONECT 352 343 354 353CONECT 353 352CONECT 354 352 355 357CONECT 355 356 354 361CONECT 356 355CONECT 357 358 354CONECT 358 357 359CONECT 359 358 360CONECT 360 359CONECT 361 355 363 362CONECT 362 361CONECT 363 361 364 366CONECT 364 365 363 370CONECT 365 364CONECT 366 367 363CONECT 367 366 368 369CONECT 368 367CONECT 369 367CONECT 370 364 372 371CONECT 371 370CONECT 372 370 373 375CONECT 373 374 372 381CONECT 374 373CONECT 375 376 372CONECT 376 375 377 378CONECT 377 376CONECT 378 376 379 380CONECT 379 378CONECT 380 378CONECT 381 373 383 382CONECT 382 381CONECT 383 381 384 386CONECT 384 385 383 391CONECT 385 384CONECT 386 387 383CONECT 387 386 388CONECT 388 387 389 390CONECT 389 388CONECT 390 399CONECT 391 384 393 392CONECT 392 391CONECT 393 396 391 394CONECT 394 395 393 399CONECT 395 394CONECT 396 393 397 398CONECT 397 396CONECT 398 396CONECT 399 394 401 400CONECT 400 399CONECT 401 399 402 404CONECT 402 403 401 412CONECT 403 402CONECT 404 405 401CONECT 405 404 406CONECT 406 405 407CONECT 407 406 408CONECT 408 407 409 410 411CONECT 409 408CONECT 410 408CONECT 411 408CONECT 412 402 414 413CONECT 413 412CONECT 414 412 415 417CONECT 415 416 414 429CONECT 416 415CONECT 417 418 414CONECT 418 417 419CONECT 419 418 420CONECT 420 419 422 421CONECT 421 420CONECT 422 420 423 426CONECT 423 422 424 425CONECT 424 423CONECT 425 423CONECT 426 422 427 428CONECT 427 426CONECT 428 426CONECT 429 415 431 430CONECT 430 429CONECT 431 434 429 432CONECT 432 433 431 435CONECT 433 432CONECT 434 431CONECT 435 432 437 436CONECT 436 435CONECT 437 435 438 440CONECT 438 439 437 447CONECT 439 438CONECT 440 441 437CONECT 441 440 442CONECT 442 441 443 444CONECT 443 442CONECT 444 442 445 446CONECT 445 444CONECT 446 444CONECT 447 438 449 448CONECT 448 447CONECT 449 447 450 452CONECT 450 451 449 464CONECT 451 450CONECT 452 453 449CONECT 453 452 454CONECT 454 453 455CONECT 455 454 457 456CONECT 456 455CONECT 457 455 458 461CONECT 458 457 459 460CONECT 459 458CONECT 460 458CONECT 461 457 462 463CONECT 462 461CONECT 463 461CONECT 464 450 466 465CONECT 465 464CONECT 466 469 464 467CONECT 467 468 466 476CONECT 468 467CONECT 469 466 470CONECT 470 469 471CONECT 471 470 472 473CONECT 472 471CONECT 473 471 475 474CONECT 474 473CONECT 475 473CONECT 476 467 478 477CONECT 477 476CONECT 478 476 479 481CONECT 479 480 478 484CONECT 480 479CONECT 481 482 483 478CONECT 482 481CONECT 483 481CONECT 484 479 486 485CONECT 485 484CONECT 486 489 484 487CONECT 487 488 486 492CONECT 488 487CONECT 489 486 490 491CONECT 490 489CONECT 491 489CONECT 492 487 494 493CONECT 493 492CONECT 494 492 495 497CONECT 495 496 494 498CONECT 496 495CONECT 497 494CONECT 498 495 500 499CONECT 499 498CONECT 500 498 501CONECT 501 502 500 503CONECT 502 501CONECT 503 501 505 504CONECT 504 503CONECT 505 503 506 508CONECT 506 507 505 512CONECT 507 506CONECT 508 509 505CONECT 509 508 510 511CONECT 510 509CONECT 511 509CONECT 512 506 514 513CONECT 513 512CONECT 514 512 515 517CONECT 515 516 514 523CONECT 516 515CONECT 517 518 514CONECT 518 517 519 520CONECT 519 518CONECT 520 518 521 522CONECT 521 520CONECT 522 520CONECT 523 515 525 524CONECT 524 523CONECT 525 523 526 528CONECT 526 527 525 535CONECT 527 526CONECT 528 529 525CONECT 529 528 530 531CONECT 530 529 532CONECT 531 529 533CONECT 532 530 534CONECT 533 531 534CONECT 534 532 533CONECT 535 526 537 536CONECT 536 535CONECT 537 535 538 540CONECT 538 539 537 552CONECT 539 538CONECT 540 541 537CONECT 541 540 542CONECT 542 541 543CONECT 543 542 545 544CONECT 544 543CONECT 545 543 546 549CONECT 546 545 547 548CONECT 547 546CONECT 548 546CONECT 549 545 550 551CONECT 550 549CONECT 551 549CONECT 552 538 554 553CONECT 553 552CONECT 554 552 555 557CONECT 555 556 554 561CONECT 556 555CONECT 557 558 559 554CONECT 558 557 560CONECT 559 557CONECT 560 558CONECT 561 555 563 562CONECT 562 561CONECT 563 561 564 566CONECT 564 565 563 570CONECT 565 564CONECT 566 567 569 563CONECT 567 566 568CONECT 568 567CONECT 569 566CONECT 570 564 572 571CONECT 571 570CONECT 572 570 573 575CONECT 573 574 572 584CONECT 574 573CONECT 575 576 572CONECT 576 575 577 578CONECT 577 576 579CONECT 578 576 580CONECT 579 577 581CONECT 580 578 581CONECT 581 579 580 582CONECT 582 581 583CONECT 583 582CONECT 584 573 586 585CONECT 585 584CONECT 586 584 587 589CONECT 587 588 586 592CONECT 588 587CONECT 589 590 586CONECT 590 589 591CONECT 591 590CONECT 592 587 594 593CONECT 593 592CONECT 594 592 595 597CONECT 595 596 594 601CONECT 596 595CONECT 597 598 599 594CONECT 598 597 600CONECT 599 597CONECT 600 598CONECT 601 595 603 602CONECT 602 601CONECT 603 601 604 606CONECT 604 605 603 609CONECT 605 604CONECT 606 607 608 603CONECT 607 606CONECT 608 606CONECT 609 604 611 610CONECT 610 609CONECT 611 609 612 614CONECT 612 613 611 621CONECT 613 612CONECT 614 615 611CONECT 615 614 616CONECT 616 615 617 618CONECT 617 616CONECT 618 616 619 620CONECT 619 618CONECT 620 618CONECT 621 612 623 622CONECT 622 621CONECT 623 626 621 624CONECT 624 625 623 630CONECT 625 624CONECT 626 623 627 629CONECT 627 626 628CONECT 628 627CONECT 629 626CONECT 630 624 632 631CONECT 631 630CONECT 632 630 632 635CONECT 633 634 632 641CONECT 634 633CONECT 635 636 632CONECT 636 635 637 638CONECT 637 636CONECT 638 636 639 640CONECT 639 638CONECT 640 638CONECT 641 633 643 642CONECT 642 641CONECT 643 646 641 644CONECT 644 645 643 648CONECT 645 644CONECT 646 643 647CONECT 647 646 762CONECT 648 649 644CONECT 649 648 650 652CONECT 650 651 649 655CONECT 651 650CONECT 652 653 649CONECT 653 652 654CONECT 654 653CONECT 655 650 657 656CONECT 656 655CONECT 657 660 655 658CONECT 658 659 657 668CONECT 659 658CONECT 660 657 661CONECT 661 660 662CONECT 662 661 663CONECT 663 662 664CONECT 664 663 667 666 665CONECT 665 664CONECT 666 664CONECT 667 664CONECT 668 658 670 669CONECT 669 668CONECT 670 668 671 673CONECT 671 672 670 678CONECT 672 671CONECT 673 674 670CONECT 674 673 675CONECT 675 674 676 677CONECT 676 675CONECT 677 675CONECT 678 671 680 679CONECT 679 678CONECT 680 678 681 683CONECT 681 682 680 689CONECT 682 681CONECT 683 684 680CONECT 684 683 685 686CONECT 685 684CONECT 686 684 687 688CONECT 687 686CONECT 688 686CONECT 689 681 691 690CONECT 690 689CONECT 691 689 692 694CONECT 692 693 691 701CONECT 693 692CONECT 694 695 691CONECT 695 694 696 697CONECT 696 695 698CONECT 697 695 699CONECT 698 696 700CONECT 699 697 700CONECT 700 698 699CONECT 701 692 703 702CONECT 702 701CONECT 703 701 704 706CONECT 704 705 703 710CONECT 705 704CONECT 706 707 703CONECT 707 706 708 709CONECT 708 707CONECT 709 707CONECT 710 712 704 711CONECT 711 710CONECT 712 710 713 715CONECT 713 714 712 722CONECT 714 713CONECT 715 716 712CONECT 716 715 717 718CONECT 717 716 719CONECT 718 716 720CONECT 719 717 721CONECT 720 718 721CONECT 721 719 720CONECT 722 713 724 723CONECT 723 722CONECT 724 722 725 727CONECT 725 726 724 731CONECT 726 725CONECT 727 728 724CONECT 728 727 729 730CONECT 729 728CONECT 730 728CONECT 731 725 733 732CONECT 732 731CONECT 733 731 734 736CONECT 734 735 733 740CONECT 735 734CONECT 736 737 739 733CONECT 737 736 738CONECT 738 737CONECT 739 736CONECT 740 734 741 746CONECT 741 740 742 744CONECT 742 743 741 747CONECT 743 742CONECT 744 745 741CONECT 745 744 746CONECT 746 745 740CONECT 747 743 749 748CONECT 748 747CONECT 749 747 750 752CONECT 750 751 749 756CONECT 751 750CONECT 752 753 749CONECT 753 752 754 755CONECT 754 753CONECT 755 753CONECT 756 750 758 757CONECT 757 756CONECT 758 756 759 761CONECT 759 760 758 763CONECT 760 759CONECT 761 762 758CONECT 762 761 647CONECT 763 759 765 764CONECT 764 763CONECT 765 763 766 768CONECT 766 767 765 776CONECT 767 766CONECT 768 769 765CONECT 769 768 770CONECT 770 769 771CONECT 771 770 772CONECT 772 771 773 774 775CONECT 773 772CONECT 774 772CONECT 775 772CONECT 776 766 778 777CONECT 777 776CONECT 778 776 779 781CONECT 779 780 778 784CONECT 780 779CONECT 781 782 778CONECT 782 781 783CONECT 783 782CONECT 784 785 779CONECT 785 784 786 788CONECT 786 787 785 792CONECT 787 786CONECT 788 789 785CONECT 789 788 790 791CONECT 790 789CONECT 791 789CONECT 792 786 794 793CONECT 793 792CONECT 794 792 795 797CONECT 795 796 794 808CONECT 796 795CONECT 797 798 794CONECT 798 797 799 800CONECT 799 798 801CONECT 800 798 803 804CONECT 801 799 803 802CONECT 802 801CONECT 803 800 801 805CONECT 804 800 806CONECT 805 803 807CONECT 806 804 807CONECT 807 805 806CONECT 808 795 810 809CONECT 809 808CONECT 810 808 811 813CONECT 811 812 810 819CONECT 812 811CONECT 813 814 810CONECT 814 813 815 816CONECT 815 814CONECT 816 814 817 818CONECT 817 816CONECT 818 816CONECT 819 811 821 820CONECT 820 819CONECT 821 819 822CONECT 822 823 821 8924CONECT 823 822CONECT 824 822 826 825CONECT 825 824CONECT 826 824 827 829CONECT 827 828 826 833CONECT 828 827CONECT 829 830 826CONECT 830 829 831 832CONECT 831 830CONECT 832 830CONECT 833 827 835 834CONECT 834 833CONECT 835 833 836 838CONECT 836 837 835 842CONECT 837 836CONECT 838 839 841 835CONECT 839 838 840CONECT 840 839CONECT 841 838CONECT 842 836 844 843CONECT 843 842CONECT 844 842 845CONECT 845 846 844 847CONECT 846 845CONECT 847 845 849 848CONECT 848 847CONECT 849 847 850 852CONECT 850 851 849 857CONECT 851 850CONECT 852 853 849CONECT 853 852 854CONECT 854 853 855 856CONECT 855 854CONECT 856 854CONECT 857 850 859 858CONECT 858 857CONECT 859 862 857 860CONECT 860 861 859 864CONECT 861 860CONECT 862 859 863CONECT 863 862 1049CONECT 864 860 866 865CONECT 865 864CONECT 866 864 867 869CONECT 867 868 8766 873CONECT 868 867CONECT 869 870 872 866CONECT 870 869 871CONECT 871 870CONECT 872 869CONECT 873 867 875 874CONECT 874 873CONECT 875 873 876 878CONECT 876 877 875 882CONECT 877 876CONECT 878 879 875CONECT 879 878 880 881CONECT 880 879CONECT 881 879CONECT 882 876 884 883CONECT 883 882CONECT 884 882 885 887CONECT 885 886 884 893CONECT 886 885CONECT 887 888 884CONECT 888 887 889 890CONECT 889 888CONECT 890 888 891 892CONECT 891 890CONECT 892 890CONECT 893 885 895 894CONECT 894 893CONECT 895 893 896 898CONECT 896 897 895 899CONECT 897 896CONECT 898 895CONECT 899 896 901 900CONECT 900 899CONECT 901 904 899 902CONECT 902 903 901 913CONECT 903 902CONECT 904 901 905CONECT 905 904 906 907CONECT 906 905 908CONECT 907 905 909CONECT 908 906 910CONECT 909 907 910CONECT 910 908 909 911CONECT 911 910 912CONECT 912 911CONECT 913 902 915 914CONECT 914 913CONECT 915 913 916 918CONECT 916 917 915 922CONECT 917 916CONECT 918 919 920 915CONECT 919 918 921CONECT 920 918CONECT 921 919CONECT 922 916 924 923CONECT 923 922CONECT 924 922 925 927CONECT 925 926 924 931CONECT 926 925CONECT 927 928 924CONECT 928 927 929 930CONECT 929 928CONECT 930 928CONECT 931 932 925CONECT 932 931 933 935CONECT 933 934 932 939CONECT 934 933CONECT 935 936 937 932CONECT 936 935 938CONECT 937 935CONECT 938 936CONECT 939 933 941 940CONECT 940 939CONECT 941 939 942 944CONECT 942 943 941 951CONECT 943 942CONECT 944 945 941CONECT 945 944 946CONECT 946 945 947 948CONECT 947 946CONECT 948 946 949 950CONECT 949 948CONECT 950 948CONECT 951 942 953 952CONECT 952 951CONECT 953 951 954 956CONECT 954 955 953 960CONECT 955 954CONECT 956 957 953CONECT 957 956 958 959CONECT 958 957CONECT 959 957CONECT 960 954 962 961CONECT 961 960CONECT 962 960 963 965CONECT 963 964 962 977CONECT 964 963CONECT 965 966 962CONECT 966 965 967CONECT 967 966 968CONECT 968 967 970 696CONECT 969 968CONECT 970 968 971 974CONECT 971 970 972 973CONECT 972 971CONECT 973 971CONECT 974 970 975 976CONECT 975 974CONECT 976 974CONECT 977 963 979 978CONECT 978 977CONECT 979 977 980 982CONECT 980 981 979 986CONECT 981 980CONECT 982 983 984 979CONECT 983 982 985CONECT 984 982CONECT 985 983CONECT 986 980 988 987CONECT 987 986CONECT 988 986 989 991CONECT 989 990 988 992CONECT 990 989CONECT 991 988CONECT 992 989 994 993CONECT 993 992CONECT 994 992 995 997CONECT 995 996 994 1000CONECT 996 995CONECT 997 998 994CONECT 998 997 999CONECT 999 998CONECT 1000 995 1002 1001CONECT 1001 1000CONECT 1002 1000 1003 1005CONECT 1003 1004 1002 1012CONECT 1004 1003CONECT 1005 1006 1002CONECT 1006 1005 1007 1008CONECT 1007 1006 1009CONECT 1008 1006 1010CONECT 1009 1007 1011CONECT 1010 1008 1011CONECT 1011 1009 1010CONECT 1012 1003 1014 1013CONECT 1013 1012CONECT 1014 1012 1015 1017CONECT 1015 1016 1014 1020CONECT 1016 1015CONECT 1017 1018 1014CONECT 1018 1017 1019CONECT 1019 1018CONECT 1020 1015 1022 1021CONECT 1021 1020CONECT 1022 1020 1023 1025CONECT 1023 1024 1022 1032CONECT 1024 1023CONECT 1025 1026 1022CONECT 1026 1025 1027CONECT 1027 1026 1028 1029CONECT 1028 1027CONECT 1029 1027 1030 1031CONECT 1030 1029CONECT 1031 1029CONECT 1032 1023 1034 1033CONECT 1033 1032CONECT 1034 1032 1035 1037CONECT 1035 1036 1034 1043CONECT 1036 1035CONECT 1037 1038 1034CONECT 1038 1037 1039 1040CONECT 1039 1038CONECT 1040 1038 1041 1042CONECT 1041 1040CONECT 1042 1040CONECT 1043 1035 1045 1044CONECT 1044 1043CONECT 1045 1043 1046 1048CONECT 1046 1047 1045 1050CONECT 1047 1046CONECT 1048 1049 1045CONECT 1049 1048 863CONECT 1050 1046 1052 1051CONECT 1051 1050CONECT 1052 1050 1053 1055CONECT 1053 1054 1052 1059CONECT 1054 1053CONECT 1055 1056 1052CONECT 1056 1055 1057 1058CONECT 1057 1056CONECT 1058 1056CONECT 1059 1053 1061 1060CONECT 1060 1059CONECT 1061 1059 1062 1064CONECT 1062 1063 1068 1061CONECT 1063 1062CONECT 1064 1065 1066 1061CONECT 1065 1064 1067CONECT 1066 1064CONECT 1067 1065CONECT 1068 1062______________________________________ __________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 2(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 amino acids(B) TYPE: amino acid(C) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:CysThrAspAsnAlaTyrIleAspIleGln510LeuArgIleAlaSerPheSerGlnAsnCys1520(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 5 amino acids(B) TYPE: amino acid(C) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:GlnValValAlaGly__________________________________________________________________________

Claims

1. A method of designing a peptide analog to domain 2 of human kininogen heavy chain comprising:

determining the distance between two parts of a molecular model of the kininogen heavy chain domain 2, at conformational equilibrium;

modifying the primary structure of the domain to restrict the distance between said two parts to the determined distance; and

synthesizing a peptide comprising said modified primary structure.

2. The method of claim 1 wherein the step of modifying the primary structure comprises introducing one or more cysteine residues to form an intramolecular disulfide bond.

3. The method of claim 1 wherein the step of modifying the primary structure comprises introducing an amino acid selected from the group consisting of lysine, glutamic acid or aspartic acid into the domain.

4. The method of claim 1 wherein the step of modifying comprises reacting side chains of a lysine and a glutamic or aspartic acid residue to form an amide bond internally cross-linking the domain.

5. The method of claim 1 wherein the step of modifying comprises introducing a toluene-2,4-diisocyanate to internally cross-link two free amino groups of the domain.

6. A method according to claim 1 wherein the molecular model comprises the set of coordinates and connect statement of Appendix 1.

7. A method of producing a peptide having a restricted conformation, comprising:

providing a peptide having an amino acid sequence which is substantially homologous to a portion of domain 2 of the human kininogen heavy chain;

determining the conformational equilibrium of that portion of domain 2; and

introducing a covalent modification into the peptide to restrict a distance between two parts of the peptide to a distance between two corresponding parts of the peptide in the equilibrium conformation determined.

8. A method according to claim 7 wherein the modification comprises a cysteine residue capable of forming an intramolecular cysteine-cysteine disulfide bond.

9. The method according to claim 7 wherein the modification comprises a molecule of toluene 2,4-diisocyanate linking two amino groups.

10. The method according to claim 7 wherein the modification comprises an amide bond cross-linking a lysine residue and a glutamic or aspartic acid residue.

11. A method according to claim 7, wherein the peptide having an amino acid sequence which is substantially homologous to a portion of domain 2 of the human kininogen heavy chain consists essentially of an amino acid sequence from about five to about fifty amino acids wherein said sequence has greater than 90% sequence identity with a segment of amino acids 124-232 of the native mature human kininogen heavy chain, and wherein the conformational equilibrium is determined from an equilibrium conformation model.

12. A method according to claim 11 wherein the equilibrium conformation model comprises the set of coordinates and connect statement of Appendix 1.

13. A method of inhibiting the activity of calpain comprising contacting calpain with:

(a) a synthetic peptide consisting essentially of an amino acid sequence of up to about 50 amino acids wherein the amino acid sequence comprises SEQ ID NO:1, said peptide having an artificially introduced restricted conformation, or

(b) a pharmaceutically acceptable salt of (a);

wherein said peptide or salt has the ability to inhibit the activity of calpain.

14. The method of claim 13 wherein the peptide or salt is attached to an additional linker sequence wherein the additional linker sequence is from about 1 to 100 amino acids.

15. The method of claim 14 wherein the linker sequence is further linked to a detectable label, solid matrix, or carrier.

16. The method of claim 13 wherein the restricted conformation is determined from an equilibrium conformation model which comprises the set of coordinates and connect statement of Appendix 1.